Menu

Onkologia - aktualności medyczne dla lekarzy

Hipec - przerzuty raka jajnika do otrzewnej - ilustracja poglądowa

Przerzuty raka jajnika do otrzewnej – jak skutecznie leczyć chirurgicznie?

25.06.2022

Dyskusja odnośnie skuteczności HIPEC w leczeniu raka jajnika toczy się od wielu lat, ale nabrała intensywności po opublikowaniu przez zespół badaczy holenderskich wyników badania OVHIPEC w roku 2018.

PTGO logo

Seksualność a choroba nowotworowa – webinar

24.06.2022

Diagnoza choroby nowotworowej oraz związanego z tym leczenia może obniżać jakość relacji intymnych pacjentek. Czy jesteśmy w stanie im pomóc? Jak prawidłowo rozmawiać z pacjentką? Gościem PTGO będzie specjalista w dziedzinie seksuologii, ginekolog onkolog prof. dr hab. Krzysztof Nowosielski.

esmo logo

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

24.06.2022

FDA granted accelerated approval to tisagenlecleucel for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Evidence for efficacy is based on the results from the ELARA study.

esmo logo

EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in Paediatric Patients

24.06.2022

EMA issued Direct Healthcare Professional Communications (DHPC) to inform healthcare professionals of the risk of ocular toxicity, severe visual loss and the need for monitoring in paediatric patients treated with crizotinib.

PTGO logo

Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka endometrium

23.06.2022

Wkrótce Polskie Towarzystwo Ginekologii Onkologicznej opublikuje nowe zalecenia dotyczące diagnostyki i leczenia raka endometrium. Powołany został zespoł do spraw opracowania zaleceń.

asco logo

Cardiovascular Health of Cancer Survivors: MARCUS Offers Improved Outcomes

23.06.2022

Cancer-directed therapies—chemotherapeutic agents, radiation, targeted therapies, and immunotherapy—can all damage the cardiovascular system, causing cancer survivors to have a higher cardiovascular mortality risk than the general population.

asco logo

Targeting TIGIT in Non–Small Cell Lung Cancer

23.06.2022

Encouraging data from the phase 2 CITYSCAPE trial led to the Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the combination of the anti-TIGIT drug tiragolumab with atezolizumab at the start of 2021.

EORTC logo

Long-term follow-up of chemoradiotherapy treatment in glioma patients shows significantly increased survival

22.06.2022

Glioma is a type of brain cancer that is rare and difficult to treat. Until quite recently, gliomas were considered to be incurable and often became rapidly fatal, but now two trials have shown that the addition of chemotherapy to radiotherapy (RT) can improve both disease control and survival in the long term for patients with a glioma.

asco logo

ASCO Releases First Comprehensive Evidence-Based Guidelines for Metastatic Clear Cell Renal Cell Carcinoma

22.06.2022

ASCO has released the first comprehensive set of guidelines for the management of metastatic clear cell renal cell carcinoma (ccRCC). The guidelines were formulated using data obtained from a systematic review of literature published between 2007 and March 2022.

asco logo

Perioperative Therapy for Early-Stage Non–Small Cell Lung Cancer: What Advances Have Been Made, and What Questions Remain?

22.06.2022

The standard of care for non–small cell lung cancer (NSCLC) is evolving, with adjuvant chemotherapy after complete resection being supplemented by treatment options such as EGFR tyrosine kinase inhibitors (TKIs) and neoadjuvant PD-L1 inhibitors.

PTChO logo

Webinar – Diagnostyka inwazyjna gruczołu sutkowego

22.06.2022

PTChO zaprasza na kolejne warsztaty z zakresu diagnostyki inwazyjnej gruczołu sutkowego. Tym razem spotkanie odbędzie się w trybie Webinaru. Jego celem jest zapoznanie uczestników z inwazyjną diagnostyką gruczołu sutkowego, głównie z systemami biopsji piersi wspomaganymi próżniowo. Termin 29.06.2022, godzina 17:00.

PTO logo

XXI Spotkanie po ASCO

22.06.2022

Pragnę zaprosić Państwa na kolejne, XXI Spotkanie Po ASCO, które odbędzie się w Gdańsku w dniach 1-2 lipca 2022 roku. Z racji utrzymującego się zagrożenia epidemicznego, w tym roku postanowiliśmy utrzymać formułę konferencji on-line. Mamy nadzieję, że interesujący program merytoryczny pozwoli choć częściowo zrekompensować Państwu brak bezpośredniego kontaktu - Jacek Jassem.

NICE logo

Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation

22.06.2022

Durvalumab is recommended as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD‑L1) on 1% or more of cells and whose disease has not progressed after platinum-based chemoradiation, only if they have had concurrent platinum-based chemoradiation.

esmo logo

Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade Squamous Intraepithelial Lesions

22.06.2022

In a phase III study, the ANCHOR Investigators Group found that participants who had undergone treatment for anal high-grade squamous intraepithelial lesions had a rate of progression to anal cancer that was 57% lower than those who had undergone active monitoring.

NCCN logo

Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

21.06.2022

New population study on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.

esmo logo

Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT for Perioperative Treatment of Resectable, HER2-positive Oesophagogastric Adenocarcinoma

21.06.2022

A randomised phase II study evaluated the clinical efficacy of the combination of trastuzumab and pertuzumab with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regimen) as perioperative treatment for patients with resectable, locally-advanced HER2–positive oesophagogastric adenocarcinoma.

ESTRO logo

Patterns of relapse after adjuvant (chemo)radiation for cervical cancer in a phase III clinical trial

20.06.2022

Study supports the use of newly published NRG/RTOG contouring guidelines in patients with cervical cancer who have undergone hysterectomy. Further data is needed to ascertain if anterior extension of the CTV is needed as in PARCER trial.

esmo logo

A Clinical Signal of Efficacy Observed with a Combination of Nivolumab and Ipilimumab Over Platinum Doublet in Fit Elderly Patients with Advanced NSCLC

20.06.2022

The authors explained in the study background that a combination of PD1 and CTLA4 monoclonal antibodies have shown superiority over chemotherapy in patients with advanced NSCLC, but data for fit elderly or patients with PS 2 are scarce.

NICE logo

NICE recommends step-change targeted treatment for people with early breast cancer

17.06.2022

NICE’s final draft guidance recommends abemaciclib for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour.

esmo logo

Carriers of a Germline Pathogenic Variant in CDKN2A are at a High Lifetime Risk of Pancreatic Ductal Adenocarcinoma

17.06.2022

Surveillance in this population leads to diagnosis of early-stage disease in one third of patients resulting in increased resectability and a substantial 5-year survival rate.

asco logo

Detecting Molecular Residual Disease to Inform CRC Treatment: Are We Ready for Universal Postoperative ctDNA Screening?

16.06.2022

Circulating tumor DNA (ctDNA), when used as a marker for minimal residual disease after curative-intent resection, is increasingly recognized as a powerful prognostic marker for patients with colorectal cancer (CRC).

asco logo

Systemic Therapies for Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: How We Treat

16.06.2022

Patients with Child-Pugh B liver cirrhosis are a heterogeneous group and should be treated based on individual scores and features of presentation.

esmo logo

No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Patients with ER-positive/HER2-negative Breast Cancer with High Genomic Grade Index

15.06.2022

A large phase III Unicancer ASTER 70s study showed that adding adjuvant chemotherapy to endocrine therapy does not result in a statistically significant overall survival benefit in patients older than 70 years with oestrogen receptor (ER)-positive, HER2-negative breast cancer with a high tumour genomic grade index.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Selinexor

15.06.2022

New indication concerns a combination of selinexor with bortezomib and dexamethasone for the treatment of multiple myeloma.

esmo logo

Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points Out to Long-Term Responses with Relapsed/Refractory Disease

14.06.2022

After nearly a 3-year follow-up for patients with relapsed/refractory mantle cell lymphoma in ZUMA-2 study, treatment with anti-CD19 chimeric antigen receptor T-cell therapy, brexucabtagene autoleucel showed durable responses and sustained survival with a manageable safety profile.

ESTRO logo

Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer

13.06.2022

The Phoenix definition remains an excellent definition for biochemical failure post-SBRT. Its high false positivity can be mitigated by applying additional criteria.

esmo logo

FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML

13.06.2022

It is approved for use in the older or patients with comorbidities who have acute myeloid leukaemia with a susceptible IDH1 mutation detected by an FDA-approved test.

esmo logo

Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

10.06.2022

In a phase I/II study, teclistamab showed substantial clinical activity that compares favourably with that of existing therapies in patients with heavily pretreated relapsed or refractory multiple myeloma.

esmo logo

Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced NSCLC

09.06.2022

In a phase II cohort study conducted among the patients with previously treated advanced KRASG12C-mutated non-small cell lung cancer (NSCLC), adagrasib showed clinical efficacy without new safety signals.

asco logo

Chemo Plus Endocrine Therapy Does Not Improve Survival in Older Patients With HER2-Negative Breast Cancer and High Tumor Genomic Grade Index

09.06.2022

Results from the Unicancer ASTER 70s trial showed that adding adjuvant chemotherapy to endocrine therapy does not result in a statistically significant survival benefit in patients older than 70 with estrogen receptor–positive, HER2-negative breast cancer with a high tumor genomic grade index.

asco logo

Promising Safety and Efficacy With Intermediate Dosing Regimen of MDM2–p53 Antagonist in Patients With Advanced or Metastatic Liposarcoma

09.06.2022

Updated phase 1a/1b data on the MDM2–p53 antagonist BI 907828 found that intermittent dosing increased the safety profile while demonstrating promising efficacy in patients with advanced for metastatic liposarcoma.

asco logo

Trastuzumab Deruxtecan Shows Encouraging Results in Patients With HER2-Expressing Biliary Tract Cancers

08.06.2022

The investigator-initiated phase 2 HERB trial of patients with HER2-positive biliary tract cancers showed that trastuzumab deruxtecan treatment leads to significant improvement in objective response rate.

asco logo

Overall Survival Increased Among Patients With Recurrent Platinum-Resistant Ovarian Cancer Who Received Intermittently Dosed Relacorilant

08.06.2022

An updated analysis of an open-label, 3-arm, phase 2, randomized trial of relacorilant plus nab-paclitaxel for patients with recurrent platinum-resistant ovarian cancer found that cortisol modulation improved median overall survival.

esmo logo

Clinical Practice Guideline – Endometrial Cancer

08.06.2022

This ESMO Clinical Practice Guideline provides key recommendations for managing endometrial cancer. The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Treatment and management algorithms according to risk-groups and for advanced/metastatic or recurrent disease are provided.

esmo logo

FDA Approves Nivolumab in Combination with Chemotherapy and Nivolumab in Combination with Ipilimumab for First-Line Treatment of Oesophageal Squamous Cell Carcinoma

08.06.2022

FDA approved the following for the first-line treatment of patients with advanced or metastatic oesophageal squamous cell carcinoma: nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy, nivolumab in combination with ipilimumab.

esmo logo

High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent PD1 Blockade

08.06.2022

In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response.

ESTRO logo

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer

07.06.2022

Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population.

esmo logo

Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive Biomarker to Improve Patients’ Selection for Pembrolizumab

07.06.2022

Findings from the PEMBROSARC study on presence of tertiary lymphoid structures in patients with advanced soft tissue sarcomas.

asco logo

Adjuvant Denosumab Improves Long-term Survival and Bone Protection in Patients With Early-Stage Breast Cancer Taking Aromatase Inhibitors

07.06.2022

The addition of the human monoclonal antibody denosumab to endocrine therapy with aromatase inhibitors (AIs) extends disease-free survival (DFS), overall survival, and bone metastasis–free survival (BMFS) while also improving bone health over a median of 8 years.

asco logo

LUMINA Trial: Omitting Radiotherapy in T1N0 Luminal A Breast Cancer Yields Low Rates of Local Recurrence

07.06.2022

The LUMINA trial prospectively evaluated the rates of recurrence in women who have undergone breast-conserving surgery for luminal A grade 1-2 T1N0 breast cancer and were treated with adjuvant endocrine therapy alone, without adjuvant radiation.

asco logo

DESTINY-Breast04 Establishes Trastuzumab Deruxtecan As a New Standard of Care for HER2-Low Metastatic Breast Cancer

06.06.2022

DESTINY-Breast04 is the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer.

asco logo

Panitumumab Combined With FOLFOX Emerges As the New First-Line PARADIGM for Left-Sided RAS Wild-Type Metastatic Colorectal Cancer

05.06.2022

PARADIGM represents the largest randomized first-line study to prospectively compare the efficacy of different targeted therapies in combination with standard doublet chemotherapy based on tumor sidedness.

asco logo

Addition of Neoadjuvant Nivolumab to Chemotherapy Improves Pathologic Complete Response in Resectable Stage IIIA NSCLC

05.06.2022

The NADIM II trial found that neoadjuvant nivolumab plus carboplatin-based chemotherapy improves pathologic complete response for patients with resectable stage IIIA NSCLC compared with chemotherapy alone, validating the results of CheckMate-816.

PTChO logo

Konkurs na najlepszą pracę dotyczącą czerniaka

04.06.2022

Polskie Towarzystwo Chirurgii Onkologicznej ogłasza konkurs na najlepszą pracę dotyczącą czerniaka opublikowaną od 2021 roku do końca czerwca 2022 roku przez zespół autorski, w którym pierwszy autor i/lub ostatni autor posiada afiliację krajowego ośrodka.

asco logo

Improving Outcomes in Pancreatic Cancer: Identifying New Targets and Testing Novel Combination Therapies

04.06.2022

During the 2022 ASCO Annual Meeting, poster presentations from 3 different studies focused on identifying new therapeutic targets and improving outcomes for patients with pancreatic cancer.

asco logo

CDK4/6 Inhibition Plus Endocrine Therapy Extends Post-Progression PFS in HR-Positive/HER2-Negative Metastatic Breast Cancer

04.06.2022

The MAINTAIN trial found a significant progression-free survival (PFS) benefit when patients with hormone receptor-positive/HER2-negative metastatic breast cancer changed endocrine therapies and received ribociclib following progression on CDK4/6 inhibitor.

asco logo

Pooled Analysis Describes Incidence and Patterns of MACE and Associated irAEs With Immune Checkpoint Inhibitor–Based Therapies

04.06.2022

This was a pooled analysis of National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP)–sponsored clinical trials immune checkpoint inhibitor (ICI) focusing on major adverse cardiac events (MACE).

asco logo

Sacituzumab Govitecan Provides PFS Benefit Over Single-Agent Chemotherapy in Heavily Pretreated HR+/HER2− Metastatic Breast Cancer

04.06.2022

Sacituzumab govitecan demonstrated a significant progression-free survival improvement over chemotherapy of physician's choice in patients with HR+/HER2− metastatic breast cancer previously treated with endocrine therapy, a CDK4/6 inhibitor, and a median of 3 lines of chemotherapy.

asco logo

Patritumab Deruxtecan Active in HER3-Expressing Metastatic Breast Cancer in Phase 1/2 Study

04.06.2022

In a phase 1/2 study, the novel HER3-targeting antibody-drug conjugate patritumab deruxtecan demonstrated activity in patients with heavily pretreated HER3-expressing metastatic breast cancer across subtypes and regardless of the level of HER3 expression.

asco logo

NRG-BR002 Trial: Adding Ablation to Systemic Therapy Fails to Boost PFS in Oligometastatic Breast Cancer

04.06.2022

Stereotactic radiotherapy or surgery for treatment metastatic lesions failed to improve progression-free survival for patients with oligometastatic breast cancer, defined as 4 or fewer metastatic lesions.

asco logo

FOENIX-CCA2 Analysis Confirms Safety and Efficacy of Futibatinib for Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements

03.06.2022

Data from the pivotal FOENIX-CCA2 trial presented during the 2022 ASCO Annual Meeting upholds previously reported efficacy and safety outcomes of futibatinib for patients with intrahepatic cholangiocarcinoma and FGFR2 fusions/rearrangements.

asco logo

Second-Line Pembrolizumab Plus Ramucirumab Extends OS Over Standard of Care in Advanced NSCLC

03.06.2022

Second-line pembrolizumab plus ramucirumab demonstrated a potential survival benefit for patients with advanced non–small cell lung cancer with immune checkpoint inhibitor resistance compared with standard-of-care regimens that included docetaxel plus ramucirumab.

asco logo

Effect of Adding Chemotherapy to First-Line Immunotherapy in Advanced NSCLC With PD-L1 ≥ 50% Varies by Age in Exploratory FDA Pooled Analysis

03.06.2022

In a retrospective pooled analysis from 12 trials in patients with previously untreated advanced non–small cell lung cancer with PD-L1 ≥ 50%, OS did not appear different between chemoimmunotherapy and immunotherapy alone across most patient subgroups.

asco logo

Immune Checkpoint Inhibitor Plus Chemotherapy Offers Similar Benefit in NSCLC Regardless of KRAS Status

03.06.2022

Patients with KRAS-mutated non–small cell lung cancer benefit similarly from the combination of an immune checkpoint inhibitor (ICI) and chemotherapy as those with wild-type disease.

asco logo

New KRAS Inhibitor Induces Responses in Non–Small Cell Lung Cancer With KRAS G12C Mutation

03.06.2022

Adagrasib, a second-in-class agent that specifically targets KRAS G12C, exhibits promising efficacy and is well tolerated in patients with previously treated advanced non–small cell lung cancer.

esmo logo

Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes

03.06.2022

Two hypomethylating agents, decitabine and 5-azacytidine are used clinically. There are many mechanisms of action of these drugs, including irreversibly binding to and inhibiting DNA methyltransferases, which result in hypomethylation and up-regulation of genes such as tumour suppressors.

asco logo

Exploring Perioperative Therapy in Pancreatic Cancer

02.06.2022

More than half of patients with localized pancreatic ductal adenocarcinoma (PDAC) have unresectable disease, and the remainder have potentially resectable tumors, either upfront resectable or borderline resectable.

asco logo

The Treatment Landscape for Cholangiocarcinoma: Rapid Evolution, Rapid Expansion

02.06.2022

The latest findings affirm that routine molecular profiling should be considered for all patients with advanced CCA, and that knowledge of targeted therapeutic agents' specific toxicities is critical to the treatment of patients with CCA.

asco logo

ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases

02.06.2022

ASCO has released a new guideline update because of new advancements in the treatment of patients with advanced HER2-positive breast cancer.

asco logo

ASCO Guideline Update Supports New Second- and Third-line Systemic Treatments for HER2-Positive Breast Cancer

02.06.2022

ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer that could inform new therapeutic algorithms and potentially alter the standard of care in systemic therapy for this patient population.

esmo logo

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia

02.06.2022

FDA approved azacitidine for paediatric patients with newly diagnosed juvenile myelomonocytic leukaemia. Efficacy was evaluated in AZA-JMML-001 (NCT02447666), an international, multicentre, open-label study.

baner konferencji XVII Usteckie Dni Onkologiczne „Powikłania w chirurgii onkologicznej”

XVII Usteckie Dni Onkologiczne „Powikłania w chirurgii onkologicznej”

03.06.2022

W dniach od 3 do 4 czerwca 2022 roku odbywa się, po dwóch latach przerwy spowodowanej pandemią COVID-19, siedemnasta już edycja konferencji Usteckie Dni Onkologiczne. W tym roku spotkanie ma miejsce jak w poprzedniej edycji w gościnnym Gdańsku.

PTChO logo

Webinar – Genetyka nowotworów i rak piersi

01.06.2022

PTChO zaprasza 9 czerwca 2022 r. (czwartek) o godz. 17.00 do udziału w webinarium organizowanym przez Fundację Polskiego Towarzystwa Chirurgii Onkologicznej pt. „Genetyka nowotworów i rak piersi”.

esmo logo

Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC

01.06.2022

Findings from the largest circulating tumour cells study in patients with metastatic renal cell carcinoma.

esmo logo

R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification of Patients with Intermediate-Risk Newly Diagnosed Multiple Myeloma

01.06.2022

Within the HARMONY project, the European Myeloma Network collected data from 10,843 patients with newly diagnosed multiple myeloma to propose a second revision (R2-ISS) of the Revised International Staging System (R-ISS).

Journal of Clinical Oncology

ASCO Guideline Update: Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

01.06.2022

This guideline update provides evidence-based recommendations to optimally use currently available biomarkers in the population of women presenting with early-stage breast cancer with known estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Pembrolizumab

31.05.2022

Extended indications concern the treatment of melanoma in adolescents aged 12 years and older and in adjuvant setting extend to Stage IIB and IIC.

ESTRO logo

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer

30.05.2022

Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel

26.05.2022

New indication concerns he treatment of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

asco logo

Gene Expression Signature May Predict Response to PD-1 Inhibition in High-Risk, HER2-Negative Early Breast Cancer

26.05.2022

A test for the expression of a set of 53 genes, called the ImPrint signature, may help predict patients with high-risk, HER2-negative early breast cancer who will respond to PD-1 inhibition, according to a subgroup analysis of the I-SPY2 phase 2 trial.

asco logo

Novel SERD Demonstrates Preliminary Efficacy in Patients With Advanced, ER-Positive Cancer

26.05.2022

New findings from a phase 1a/1b trial (Abstract 1021) show that the novel SERD imlunestrant is safe and demonstrated preliminary efficacy in ER-positive advanced breast cancer and endometrial endometrioid cancer.

asco logo

Two Clinical Trials on CDK4/6 Inhibitors for HR-Positive Breast Cancer Reveal Distinct Quality of Life Outcomes

26.05.2022

A comparative effectiveness analysis between 2 randomized clinical trials found ribociclib plus aromatase inhibitor (AI) to be associated with better patient-reported quality of life compared with abemaciclib plus AI as a first-line treatment for hormone receptor (HR)–positive, HER2-negative advanced breast cancer.

asco logo

Reduced-Dose Exemestane Noninferior to Standard Daily Dose in Postmenopausal Women With Early ER-Positive Breast Cancer

26.05.2022

Findings from a noninferiority phase 2b biomarker study indicate that the aromatase inhibitor exemestane taken 3 times per week is noninferior to the standard daily dose among postmenopausal women with estrogen receptor-positive breast cancer.

asco logo

Surgery or Radiofrequency Ablation for Early-Stage HCC? Japanese SURF Data Support Either Approach

26.05.2022

Collective findings from the SURF study conducted in Japan indicate that surgery and radiofrequency ablation (RFA) confer similar long-term outcomes when used in patients with early-stage hepatocellular carcinoma (HCC).

asco logo

Significant Discrepancies Found Among PD-L1 Assays Used in Gastric Cancer

26.05.2022

The different immunohistochemistry (IHC) assays available to test for PD-L1 positivity in patients with gastric cancer yield significantly discordant results.

asco logo

Taking the Unconventional Route: Locoregional Administration of Novel Pharmacotherapies Shows Promise

26.05.2022

A key shortcoming of select systemic anticancer therapies is limited penetration into solid tumors. One potential solution is to deliver highly active drugs locoregionally at the site of the malignant lesions, thereby maximizing the cytotoxic effects while minimizing systemic toxicity.

asco logo

Personalized mRNA Vaccine Is Feasible and Immunogenic in Pancreatic Ductal Adenocarcinoma

26.05.2022

A personalized neoantigen-specific immunotherapy vaccine is immunogenic in pancreatic ductal adenocarcinoma (PDAC) and can be manufactured in real time and delivered in a median of 9 weeks following surgery, according to findings from an investigator-initiated phase 1 trial (Abstract 2516).

asco logo

Durvalumab Yields Similar Survival Outcomes to Placebo in Patients With Stage III EGFR-Mutant NSCLC

26.05.2022

A post hoc exploratory analysis of 35 participants from the PACIFIC trial with stage III EGFR-mutation positive (EGFRm) non–small cell lung cancer (NSCLC) indicated a similar survival benefit of durvalumab treatment versus placebo.

asco logo

Stereotactic Radiosurgery Demonstrates Similar Survival Outcomes as Whole-Brain Radiation in SCLC and IMD

26.05.2022

New research findings suggest stereotactic radiosurgery (SRS) may be associated with comparable survival outcomes to whole-brain radiation therapy in patients with small cell lung cancer (SCLC) and intracranial metastatic disease.

asco logo

Improving Outcomes in NSCLC: Understanding the Mechanisms of Resistance to ICIs and Expanding Treatment Options With Bispecific Antibodies

26.05.2022

Despite drastic improvement in survival brought on by the approval of immune checkpoint inhibitors for non–small cell lung cancer, less than 50% of patients with advanced NSCLC do not respond to immunotherapy and, of those who achieve an initial response, a significant fraction will progress over time.

asco logo

Lurbinectedin Monotherapy Continuation After Induction of Lurbinectedin/Doxorubicin Is Associated With Prolonged OS in Advanced SCLC

26.05.2022

New data suggest patients experience similar, and in some cases better, tumor response from switching to monotherapy with the novel drug lurbinectedin following administration of combination lurbinectedin/doxorubicin.

PTGO logo

Stanowisko PTGO w sprawie dawki Bewacizumabu stosowanej w I linii leczenia chorych z rakiem jajnika po 1 maja 2022r

25.05.2022

W związku ze zmianami sposobu refundacji leku bewacizumab, Polskie Towarzystwo Ginekologii Onkologicznej w oparciu o badania kliniczne, opinie AOTMiT oraz doświadczenia własne, przedstawia opinię dotyczącą dawki bewacizumabu stosowanej w I linii w leczeniu chorych z rakiem jajnika.

NICE logo

New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE

25.05.2022

People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) following the final draft recommendation from NICE.

esmo logo

Copanlisib Could Be a Viable Therapeutic Option for Select PIK3CA-Mutated Cancers

25.05.2022

Arm Z1F of the NCI-MATCH study run by ECOG-ACRIN met a primary endpoint with copanlisib, showing promising clinical activity in select PIK3CA-mutated cancers in the late-line, refractory setting.

esmo logo

Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of Cancer Core Europe

25.05.2022

An academic clinical decision support system to better address the challenges of delivering biomarker-driven oncology.

asco logo

Educational Session Provides Updates on the AML Treatment Landscape for Older Adults

25.05.2022

The 2022 ASCO Annual Meeting will feature the Education Session “Contemporary Treatment of Older Adults with Acute Myeloid Leukemia: Merging the Science with Clinical Practice”.

AOTMiT logo

Pozytywna opinia AOTMiT w sprawie refundacji capecitabinum w leczeniu raka trzustki

24.05.2022

Rada Przejrzystości AOTMiT uznaje za zasadną kontynuację refundacji leków zawierających substancję czynną capecitabinum w terapii nowotwóru złośliwego trzustki w ramach uzupełniającego leczenia pooperacyjnego trzustki w skojarzeniu z gemcytabiną.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Atezolizumab

24.05.2022

New indication concerns the adjuvant treatment of patients with early-stage non-small cell lung cancer.

ESTRO logo

Is Radiation-Induced Cardiac Toxicity Reversible? Prospective Evaluation of Patients With Breast Cancer

23.05.2022

RT was associated with short-term perfusion defects that improved within one year and was not correlated with late cardiac events. The ventricular volumes receiving 5.0 Gy and 10 Gy were correlated with late cardiac events.

esmo logo

HBV Infection Associated with Increased Risk of Primary Extrahepatic Malignancies

23.05.2022

The study that evaluated the associations of chronic hepatitis B and nucleos(t)ide analogue treatment with the risk of the development of extrahepatic malignancies point out to a need for more attention to the higher risk of extrahepatic malignancy in patients with chronic hepatitis B than in the general population.

ESTRO logo

GEC-ESTRO ACROP Prostate Brachytherapy Guidelines

20.05.2022

This is an evidence-based guideline for prostate brachytherapy. Throughout levels of evidence quoted are those from the Oxford Centre for Evidence based Medicine.

esmo logo

Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal Cancers Detected Otherwise

20.05.2022

The authors concluded that the proportion of colorectal cancer cases detected by screening varied widely between countries and regions. However, in all countries, screen-detected cancers had a more favourable stage distribution than cancers detected otherwise.

Journal of Clinical Oncology

ASCO Guideline Rapid Recommendation Update: Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer

20.05.2022

This American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Recommendation Update provides a recommendation update, with review and analysis of the relevant literature for the recommendation.

asco logo

Education Session Focuses on Latest Developments in Treating KRAS-Mutant Lung Cancer

19.05.2022

The Education Session will discuss the history and challenges of treating KRAS mutations, the CodeBreaK 100 trial, and what's next in the KRAS inhibitor pipeline.

esmo logo

EMA Starts Review of Rucaparib

19.05.2022

The review follows interim results from the ongoing ARIEL4 study indicating that overall survival was shorter in patients treated with rucaparib than in those who received chemotherapy.

PTGO logo

Chirurgia w raku jajnika – webinar

18.05.2022

Niespecyficzne objawy kliniczne powodują opóźnienie diagnostyki, a w konsekwencji rozpoznanie raka jajnika w stadium rozsianej choroby. Wybór metody leczenia zależy od stopnia zaawansowania tego nowotworu. Chirurgia jest niezwykle ważnym elementem całego procesu diagnostyczno-terapeutycznego.

asco logo

ASCO Guideline Endorses Exercise, Discusses Diet and Weight Management During Cancer Treatment

18.05.2022

A new ASCO guideline offers evidence-based recommendations for exercise, diet, and weight management during cancer treatment with the hope these recommendations will mitigate treatment-related side effects of cancer therapy and reduce the risk of postoperative complications associated with certain interventions.

esmo logo

Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing in Young Adults

18.05.2022

Group of investigators from UK and Australia found that the incidence of colorectal, breast, kidney, pancreatic, and uterine cancers is increasing in younger age groups, whilst the incidence of lung, laryngeal and bladder cancers is decreasing.

NICE logo

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations

18.05.2022

Tepotinib is recommended as an option for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab

17.05.2022

EMA adopted a positive opinion for the medicinal product mosunetuzumab, intended for the treatment of relapsed or refractory follicular lymphoma.

NICE logo

Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread

17.05.2022

A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance.

ESTRO logo

Quality of Life After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy

16.05.2022

Palliative RT improves QoL. Both SBRT and cRT have a comparable effect on patient-reported QoL outcomes in patients with painful bone metastases. Functional interference and psychological aspects scores improved more in patients treated with cRT versus patients offered SBRT.

esmo logo

Long-Term Responders with No Evidence of Disease Have Better Survival to First-Line HER2 Targeted Therapy for MBC

16.05.2022

Evaluation of clinical characteristics of patients with HER2-positive metastatic breast cancer with no evidence of disease (NED) versus those with residual disease experiencing long-term response to first-line HER2-targeted therapy showed that those with NED status have better survival.

NICE logo

More people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use

16.05.2022

NICE has published a draft final appraisal document recommending Durvalumab as an option for treating non-small-cell lung cancer (NSCLC) in adults.

AACR logo

Adolescent and Young Adult Leukemia Survivors Face Higher Mortality Rates Than the General Population for Decades After Diagnosis

13.05.2022

The long-term survival of adolescent and young adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) survivors was shorter than that of the general population, and the differences persisted for up to 30 years after diagnosis.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Capmatinib

13.05.2022

EMA adopted a positive opinion for the medicinal product capmatinib, intended for treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.

ESTRO logo

Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer

13.05.2022

We examined the literature to issue new recommendations on active surveillance (AS) for managing localised prostate cancer.

PTOK logo

Modernizacja systemu e-KRN+ i Polski Rejestr Onko-Hematologiczny (PROH)

12.05.2022

Jeszcze w tym roku uruchomiony zostanie nowy system e-KRN+ oraz pierwszy rejestr narządowy – Polski Rejestr Onko-Hematologiczny (PROH). W związku w tym, zespół Krajowego Rejestru Nowotworów zaprasza pracowników placówek medycznych na spotkanie informacyjne, podczas którego zostaną omówione szczegóły techniczne i organizacyjne planowanych zmian.

esmo logo

Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and Ipilimumab Combined with SBRT for Refractory Metastatic Pancreatic Cancer

12.05.2022

First prospective evaluation demonstrates a clinical benefit and safety of stereotactic body radiotherapy (SBRT) in combination with nivolumab and ipilimumab in pretreated patients with refractory metastatic pancreatic cancer.

esmo logo

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy

11.05.2022

Avelumab is recommended as an option for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults, only if avelumab is stopped at 5 years of uninterrupted treatment or earlier if the disease progresses.

esmo logo

Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient Care Experience and Optimises Healthcare Resources

11.05.2022

In a single-centre, randomised phase III CAPRI study that compared an intervention combining nurse navigator-led follow-up and a smartphone application on top of usual care versus usual care in patients with advanced cancers treated with oral anticancer drugs met its primary endpoint of significant improvement in relative dose intensity.

ASTRO logo

ASTRO issues clinical guideline on radiation therapy for brain metastases

10.05.2022

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to manage intact and resected brain metastases from non-hematologic solid tumors.

EORTC logo

Results of radiotherapy quality assurance in the PEACE-1 trial show high adherence to protocol

10.05.2022

The multi-centre EORTC PEACE-1 Phase 3 trial examines the effect of Abiraterone on men with metastatic hormone-naïve1 prostate cancer. Patients have been randomised into groups studying the impact of standard therapy with or without radiotherapy and standard treatment plus Abiraterone with or without radiotherapy.

esmo logo

Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did Not Compromise Efficacy in Asian Patients with Stage III Colon Cancer

00.05.2022

In Asian patients with stage III colon cancer, shortening duration of adjuvant treatment from 6 to 3 months did not compromise efficacy. Disease-free survival (DFS) and overall survival (OS) at 5 years were comparable in the 3-month and 6-month treatment groups.

ESTRO logo

Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone Analogs in Combination With Radiation Therapy

09.05.2022

CHHiP is a randomised trial evaluating moderately hypofractionated radiation therapy for treatment of localised prostate cancer. This exploratory analysis compares efficacy and side effects in a nonrandomised comparison.

esmo logo

FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Breast Cancer

09.05.2022

FDA approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.

PTChO logo

Konkurs na najlepszą pracę polskich autorów dotyczącą czerniaka 2022

06.05.2022

Polskie Towarzystwo Chirurgii Onkologicznej ogłasza konkurs na najlepszą pracę dotyczącą czerniaka opublikowaną od 2021 roku do końca czerwca 2022 roku przez zespół autorski, w którym pierwszy autor i/lub ostatni autor posiada afiliację krajowego ośrodka.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Pembrolizumab

06.05.2022

New indication concerns a neoadjuvant and adjuvant treatment of adult patients with triple negative breast cancer at high risk of recurrence.

esmo logo

Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar High-Grade Squamous Intraepithelial Lesions

05.05.2022

According to findings from a multicentre, randomised, phase III, non-inferiority study imiquimod is a safe, effective, and well accepted alternative to surgery for women with vulvar high-grade squamous intraepithelial lesions and can be considered as first-line treatment.

asco logo

ASCO22 to Address Updates and Needs in Managing and Detecting Breast Malignancies

05.05.2022

As a reflection of both how far breast cancer treatment has come and how much progress is still needed, a trio of Education Sessions at the 2022 ASCO Annual Meeting will discuss some of the latest advances in managing breast malignancies.

asco logo

Education Session to Discuss New and Upcoming Treatments for Germline Malignancies

05.05.2022

The upcoming 2022 ASCO Annual Meeting Education Session “Novel Therapies in Germline Syndromes” will discuss the recent advances in treatments for inherited disease.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel

04.05.2022

New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

asco logo

Education Session to Address the Increasing Complexity of Treatment Sequencing in Resectable Lung Cancer

04.05.2022

A 2022 ASCO Annual Meeting Education Session, “Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy,” will address these questions, clarifying which interventions garner the best outcomes in the adjuvant and neoadjuvant setting.

esmo logo

Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in Patients with Resectable NSCLC

03.05.2022

Findings from a phase III study show that neoadjuvant nivolumab plus chemotherapy had a significant benefit over chemotherapy alone with respect to event-free survival and pathological complete response and had no adverse effect on surgical feasibility or surgical outcomes in patients with resectable stage IB to IIIA non-small cell lung cancer.

esmo logo

Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival in De Novo Metastatic Castration-Sensitive Prostate Cancer

02.05.2022

Combining androgen deprivation therapy, docetaxel, and abiraterone plus prednisone in patients with de novo metastatic castration-sensitive prostate cancer improved coprimary endpoints of radiographic progression-free survival and overall survival with a modest increase in side effects, mostly hypertension, according to findings from the PEACE-1 study.

ESTRO logo

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer

02.05.2022

Sugemalimab after definitive concurrent or sequential chemoradiotherapy could be an effective consolidation therapy for patients with stage III NSCLC whose disease has not progressed after sequential or concurrent chemoradiotherapy. Longer follow-up is needed to confirm this conclusion.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Cabozantinib

29.04.2022

Cabozantinib is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.

esmo logo

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer

28.04.2022

This special article provides updated treatment recommendations on thyroid cancer. New targeted systemic therapies have now been approved for treating patients with advanced/metastatic thyroid cancers. This article summarises these new options and the order in which they should be used.

esmo logo

Increased Risk of Cancer in Early Life Among Individuals with Autism Spectrum Disorders

28.04.2022

In the largest and most detailed population-based cohort study to date, the researchers from the Karolinska Institutet in Stockholm, Sweden found that individuals with autism spectrum disorders, when present with comorbid intellectual disability and/or birth defects, were at a higher risk of cancer in early life, compared with individuals without autism spectrum disorders.

asco logo

Managing Immune-Related Adverse Events in Patients With Metastatic Non–Small Cell Lung Cancer

28.04.2022

A comprehensive multidisciplinary approach is crucial to accurately diagnosing and optimally managing immune-related adverse events (irAEs) in patients with metastatic non–small cell lung cancer.

asco logo

ASCO Refines Guidance on Using Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

27.04.2022

A new ASCO guideline update provides further recommendations on the use of biomarkers to guide decision-making on adjuvant endocrine therapy and chemotherapy in patients with early-stage breast cancer.

asco logo

Education Session to Highlight Immunotherapies As Emerging Targets of Prostate Cancer Treatment Development

27.04.2022

With the advent of immunotherapies helping to drive improvements in cancer survival and disease recurrence, a growing number of phase 3 clinical trials are underway or in development to investigate these groundbreaking treatments in prostate cancer.

NICE logo

Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies

27.04.2022

Tucatinib with trastuzumab and capecitabine is recommended, within its marketing authorisation, as an option for treating HER2‑positive locally advanced or metastatic breast cancer in adults after 2 or more anti‑HER2 treatment therapies.

esmo logo

Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with Newly Diagnosed IDH1-Mutated AML

26.04.2022

In a phase III, AGILE study, ivosidenib and azacitidine significantly improved event-free survival (EFS), response, and overall survival (OS) as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated acute myeloid leukaemia (AML) who were ineligible for induction chemotherapy.

ESTRO logo

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy

25.04.2022

Patients with non-small-cell lung cancer that are resistant to PD-1 and PD-L1 targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated the potential benefit of PD-L1 (durvalumab) and CTLA-4 (tremelimumab) inhibition alone or combined with radiotherapy.

esmo logo

Enzalutamide Plus ADT Significantly Prolongs Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

25.04.2022

Enzalutamide in combination with androgen deprivation therapy (ADT) showed clinical benefits in the phase III ARCHES study for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC).

ptcho logo

Drugie spotkanie z hybrydowego cyklu Akademia Czerniaka 2022

22.04.2022

PTChO serdecznie zaprasza do udziału w drugim spotkaniu z hybrydowego cyklu Akademia Czerniaka 2022. Wydarzenie odbędzie się 20 maja. Udział online lub osobisty w Hotel Tarnovia w Tarnowie. Przewodniczący Komitetu Naukowego: prof. dr hab. n. med. Piotr Rutkowski.

ptgo logo

Z patomorfologią za pan brat! – webinar

22.04.2022

Do czego służy badanie śródoperacyjne? Czy może stanowić ostateczne rozpoznanie? Jak prawidłowo pobrać materiał do badania histopatologicznego? Na czym polega ocena badania cytologicznego szyjki macicy? Te i wiele więcej zagadnień poruszymy spotkaniu z prof. Andrzejem Marszałkiem – wybitnym patomorfologiem.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel

22.04.2022

It is intended for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies.

ViaMedica logo

Konferencja Od genetyki do kliniki

21.04.2022

ViaMedica zaprasza do udziału w konferencji Od genetyki do kliniki, która odbędzie się w formule hybrydowej. Wydarzenie odbędzie się 13-14 maja. Udział online lub osobisty w Hotel Best Western Plus Olsztyn. dr hab. n. med. Tomasz Kubiatowski, prof. CMKP.

esmo logo

Clinical Practice Guideline – The Role of Patient-Reported Outcome Measures in the Continuum of Cancer Clinical Care

21.04.2022

This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer. It covers the use of PROMs in patients with cancer from the start of active treatment during follow-up and at the end of life. Recommendations are based on available scientific evidence and the authors’ collective expert consensus.

NICE logo

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

20.04.2022

Niraparib is recommended as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults.

asco logo

Defining the Role of Lutetium-PSMA and Other PSMA-Targeted Therapies in Prostate Cancer

20.04.2022

The VISION study recently demonstrated that LuPSMA prolongs survival for men with metastatic castration-resistant prostate cancer and has a favorable safety profile.

asco logo

ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage TNBC

20.04.2022

A rapid update to the ASCO guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer. The update follows a recent analysis from the randomized phase 3 KEYNOTE-522 trial that showed a significant event-free survival benefit.

Journal of Clinical Oncology

ASCO Guideline: Management of Stage III Non–Small-Cell Lung Cancer

20.04.2022

Evidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.

ESTRO logo

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression

19.04.2022

The addition of trastuzumab to neoadjuvant chemoradiotherapy for HER2-overexpressing oesophageal cancer was not effective. Trastuzumab did not lead to increased toxicities, suggesting that future studies combining it with or using other agents targeting HER2 in oesophageal cancer are warranted.

esmo logo

Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC

19.04.2022

In patients included in MyPathway, a multi-basket study assessing approved therapies in non-indicated advanced solid tumours with relevant alterations, alectinib showed activity in patients with ALK-rearranged advanced solid tumours other than non-small cell lung cancer.

esmo logo

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

15.04.2022

FDA approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin

14.04.2022

Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

asco logo

‘Doctor, What Should I Eat?’ Dietary Counseling for Patients With Cancer

14.04.2022

Nutrition affects morbidity and mortality in patients with cancer, yet oncologists do not adequately address this issue. When it comes to patients with cancer—whether newly diagnosed, in active treatment, or in survivorship — an important point to consider in dietary guidance is avoidance of overly rigid rules for eating.

asco logo

Considerations for First-Line Metastatic Melanoma: Which Treatment Is Best?

13.04.2022

For metastatic melanoma, which should be used in the first-line setting: PD-1 plus LAG-3 inhibitor therapy or PD-1 plus CTLA-4 inhibitor therapy? What is the role of BRAF/MEK in patients with BRAF-mutant disease?

NIL logo

Prehabilitacja

13.04.2022

NIL wspólnie z Towarzystwem Chirurgów Polskich zaprasza chirurgów i lekarzy dyscyplin zabiegowych na szkolenie. W programie: Jak wykorzystać czas przed operacją by przygotować pacjenta do zabiegu, Prehablitacja w pigułce – to prostsze niż nazwa wskazuje, Kierunek zdrowie – prehabilitacja w praktyce. Prowadzący: Prof. Tomasz Banasiewicz.

NICE logo

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma

13.04.2022

Daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment.

esmo logo

FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable or Metastatic Melanoma

12.04.2022

FDA approved nivolumab and relatlimab-rmbw (Opdualag) for adult and paediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the PD1-blocking antibody nivolumab.

AACR logo

Leukemia Patients With Certain Gene Regulation Patterns May Be Less Likely to Respond to CAR T Therapy

12.04.2022

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022.

AACR logo

Accounting for Genetic Factors that Cause Normal Variations in PSA Levels May Improve the Accuracy of Prostate Cancer Detection

11.04.2022

The accuracy of prostate-specific antigen (PSA) screening for prostate cancer could be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, according to data presented during the AACR Annual Meeting 2022.

esmo logo

Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

11.04.2022

The phase III KEYNOTE-048 study investigated pembrolizumab monotherapy or pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy in patients with previously untreated recurrent or metastatic HNSCC.

lekarze – ilustracja poglądowa

Odpowiedzialność Cywilna Lekarza

11.04.2022

Lekarz od wieków pozostaje zawodem o bardzo wysokim poziomie zaufania społecznego. Jednak nawet lekarze pozostają tylko ludźmi, a co za tym idzie, nie są nieomylni. Dlatego też, zaczynając pracę w tej profesji, warto zapoznać się z tematem lekarskiej odpowiedzialności cywilnej, a także ubezpieczeń od tejże odpowiedzialności.

Journal of Clinical Oncology

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

10.04.2022

The approval of abemaciclib in adjuvant EBC was limited to patients with high risk of recurrence and Ki-67 ≥ 20%, given their favorable benefit:risk with a statistically significant IDFS advantage and no observed detriment on survival.

Journal of Clinical Oncology

Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

10.04.2022

Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease.

AACR logo

New CAR T-cell Therapy for Solid Tumors Was Safe and Showed Early Efficacy

10.04.2022

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial.

AACR logo

KRAS G12C Inhibitor Sotorasib May Offer Long-term Clinical Benefit in Patients with Non-small Cell Lung Cancer

10.04.2022

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial.

esmo logo

Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in Patients with Previously Treated Progressive Classical Kaposi Sarcoma

08.04.2022

In a prospective, phase II study that assessed the efficacy of nivolumab in combination with low-dose ipilimumab in patients with previously treated classical Kaposi sarcoma, the study team observed high response rates and prolonged duration of response with tolerable toxicity.

ESTRO logo

Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer

07.04.2022

Our findings provide the strongest level of evidence so far to the magnitude of the benefit of ADT treatment intensification with radiotherapy for men with localised prostate cancer. Adding ADT and prolonging the portion of ADT that follows radiotherapy is associated with improved metastasis-free survival in men.

esmo logo

EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR Cancers and to Metastatic Cervical Cancer with PD-L1 CPS ≥1

07.04.2022

New indications concern the treatment of patients with MSI-H or dMMR advanced colorectal, endometrial, gastric, small intestine, or biliary cancers, and PD-L1-positive metastatic cervical cancer.

asco logo

Is It Time to Routinely Use Circulating Tumor DNA to Guide Colon Cancer Adjuvant Therapy?

06.04.2022

In recent years, circulating tumor DNA has been evaluated in many cancer types and settings, including screening, diagnosing, detecting residual disease, guiding adjuvant therapy, detecting recurrence, monitoring response to therapy, defining mutational profile, and identifying resistance mechanisms.

esmo logo

Benefit of Adjuvant Capecitabine After Curative Resection of Biliary Tract Cancer Maintained with a Long-Term Analysis

06.04.2022

The long-term (5-year) survival data from the BILCAP study confirm the benefit of capecitabine as adjuvant therapy after surgical resection of biliary tract cancer and it should be considered as the standard of care.

PTGO logo

Nowa rejestracja w raku endometrium

05.04.2022

Europejska Agencja Leków (EMA) wydała pozytywną rekomendację dla stosowania pembrolizumabu do leczenia chorych z guzami MSI-H lub dMMR w zaawansowanym lub nawrotowym raku endometrium z progresją w trakcie lub po leczeniu chemioterapią opartą na związkach platyny.

esmo logo

FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma

05.04.2022

FDA approved pembrolizumab as a single agent, for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.

ViaMedica logo

Kobiety specjalistki kobietom pacjentkom. Życie po leczeniu raka piersi

04.04.2022

Konferencja w całości poświęcona jest omówieniu wyników badań patomorfologicznych, genetycznych i molekularnych. Gwałtowny rozwój nowych metod leczenia raka piersi, jaki nastąpił w ciągu ostatnich lat, sprawił że pacjentkom może być trudno poruszać się w gąszczu obco brzmiących terminów. Dlatego chcemy przedstawić nowe czynniki, decydujące o odpowiednim doborze leczenia, jak również nieco uporządkować wiedzę o tych znanych już wcześniej.

ESTRO logo

Nivolumab Combination Therapy in Advanced Oesophageal Squamous-Cell Carcinoma

04.04.2022

Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced oesophageal squamous-cell carcinoma.

esmo logo

BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy are at Increased Risk of Peritoneal Carcinomatosis

04.04.2022

The authors concluded that BRCA1/2 pathogenic variant carriers with serous tubal intraepithelial carcinoma at risk-reducing salpingo-oophorectomy are at increased risk of peritoneal carcinomatosis.

esmo logo

ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to Identify Patients Who May Benefit from Further Therapeutic Intervention

01.04.2022

The authors concluded that analysis of ctDNA before and after treatment with curative intent of patients with early-stage NSCLC demonstrated that detection of ctDNA using sensitive personalised assays can inform patient prognosis and help guide patient treatment.

EORTC logo

Joining forces to optimise cancer treatments in clinical practice: EMA & EORTC launch Cancer Medicines Forum with academia

01.04.2022

A significant step at the European level and in terms of regulatory science, the European Medicines Agency together with the European Organisation for Research and Treatment of Cancer has launched the Cancer Medicines Forum. The forum aims at advancing research into optimising cancer treatments and will contribute to foster high standards in cancer care in the European Union.

ESTRO logo

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases

31.03.2022

To our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population.

NCCN logo

NCCN Annual Conference Focuses on Cancer Patient Journey; with Cutting-Edge Research and Latest Evidence-Based Care Recommendations

31.03.2022

The NCCN 2022 Annual Conference brings together more than a thousand oncology professionals from around the world to learn about the latest evidence-based treatment recommendations and evaluate new research.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Tebentafusp

31.03.2022

EMA adopted a positive opinion for the medicinal product tebentafusp indicated as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive adult patients with unresectable or metastatic uveal melanoma.

Journal of Clinical Oncology

ASCO Guideline Rapid Recommendation Update: Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer

01.04.2022

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review.

ESSO logo

ESSO Course on Fluorescence Guided Surgery

30.03.2022

In this course participants will obtain a thorough knowledge of the fundamentals and state-of-the-art applications of fluorescence imaging of tumors (primary, metastases, lymph nodes), sentinel lymph nodes and lymphatics, vital structures (bile ducts, ureters, nerves) and perfusion assessment of organs and tissues.

esmo logo

Tumour Budding Demonstrates Independent Prognostic Value for Disease-Free and Overall Survival in Patients with Stage III Colon Cancer

30.03.2022

Tumour budding is an emerging prognostic biomarker in colon cancer and currently influences decision-making in patients with pT1 and stage II colon cancer. In stage III colon cancer, its prognostic impact has been limited to small and retrospective cohorts.

NICE logo

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

30.03.2022

Sotorasib is recommended for use as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy.

esmo logo

The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer

29.03.2022

Patients with cancer, especially haematologic malignancies, are at higher risk for developing breakthrough infections and severe outcomes. The findings were published in the Journal of Clinical Oncology.

esmo logo

Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors

28.03.2022

New mechanisms of genomic escape from established covalent and novel non-covalent Bruton’s tyrosine kinase inhibitors described. The findings were published in the New England Journal of Medicine.

PTGO logo

Endometrioza a rak jajnika – webinar

25.03.2022

Czy komórki endometriozy ulegają nowotworzeniu? Jakie są czynniki ryzyka sprzyjające transformacji endometriozy w raka jajnika? Co to są nowotwory jajnika typu low-grade? Na te i inne pytania odpowie ekspert w dziedzinie ginekologii onkologicznej, Pani Prof. Anita Chudecka-Głaz.

esmo logo

FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

25.03.2022

FDA approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

NICE logo

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

24.03.2022

Nivolumab with ipilimumab is recommended, within its marketing authorisation, as an option for untreated advanced renal cell carcinoma in adults whose disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria

esmo logo

EMA Recommends Granting a Marketing Authorisation for Relugolix

24.03.2022

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product relugolix, intended for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

ASCO logo

Precision Immunotherapy Developments in Microsatellite Stable (MSS) Gastroesophageal Cancer: Can We Use a Key Instead of a Hammer?

23.03.2022

CheckMate-649 and KEYNOTE-590 trials validated the advantage of adding PD-1 inhibitors nivolumab and pembrolizumab, respectively, to 5-FU–based chemotherapy regimens in patients with advanced, chemotherapy-naive gastroesophageal cancer.

esmo logo

A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer Undergoing Thyroidectomy

23.03.2022

In a prospective, randomised phase III study that involved patients with low-risk differentiated thyroid cancer, follow-up without the use of radioiodine after thyroidectomy was not inferior to the administration of 1.1 GBq of radioiodine after the administration of recombinant human thyrotropin.

esmo logo

First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival Benefit in HR-positive, HER2-negative Advanced Breast Cancer

22.03.2022

First-line treatment with ribociclib plus letrozole showed a significant overall survival (OS) benefit as compared with placebo plus letrozole in postmenopausal patients with HR-positive, HER2-negative advanced breast cancer.

ViaMedica logo

Akademia Czerniaka 2022

21.03.2022

Organizator cyklu konferencji Akademia Czerniaka 2022 zaprasza na pierwszą w tym roku konferencję, która odbędzie się w Gdańsku, 1 kwietnia, o godz. 14:00. W konferencji można uczestniczyć online lub stacjonarnie* w Gdańsku w Hotelu Scandic. Zostaną omówione: leczenie uzupełniające, leczenie przerzutów in-transit i wznowy miejscowej, inne nowotwory skóry (DFPS, zaawansowany BCC, SCC, rak z komórek Merkla), sytuacje specjalne - leczenie przerzutów do mózgu, czerniaki błon śluzowych, czerniak z nieznanego ogniska pierwotnego.

esmo logo

Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with Acceptable Toxicity in Locally Advanced Rectal Cancer

21.03.2022

A randomised, phase III STELLAR study evaluated whether a total neoadjuvant therapy approach comprising hypofractionated radiation (5 Gy × 5) followed by chemotherapy is non-inferior to standard chemoradiotherapy (CRT) in patients with locally advanced rectal cancer.

esmo logo

FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

18.03.2022

FDA approved olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

EORTC logo

Pembrolizumab Significantly Improved Disease-Free Survival Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

17.03.2022

EORTC announced results from the pivotal Phase 3 KEYNOTE-091 trial. The study found that adjuvant treatment with KEYTRUDA significantly improved disease-free survival, one of the dual primary endpoints, reducing the risk of disease recurrence or death by 24% compared to placebo.

esmo logo

EMA Adopts a Revised Opinion for Enfortumab Vedotin After Further Safety Information Emerged During the Decision-Making Process

17.03.2022

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product enfortumab vedotin, intended for the treatment of adult patients with urothelial cancer.

asco logo

ASCO Guidelines Emphasize Crucial Role Biomarkers Play in Treatment Selection for HER2-Negative Breast Cancer

16.03.2022

In this article, we provide a brief summary of the guideline updates and clinical practice considerations for the treatment of hormone receptor (HR)–positive and HR-negative/HER2-negative metastatic breast cancer.

esmo logo

Risk Estimates of Small Bowel Cancer in Inflammatory Bowel Disease

16.03.2022

A population-based cohort study of all patients with inflammatory bowel disease diagnosed in Norway and Sweden from 1987 through 2016 was conducted to quantify the risk of small bowel adenocarcinoma and neuroendocrine tumours in patients with ulcerative colitis and Crohn’s disease.

AACR logo

Genomic Profiling of Pediatric Cancer May Expand Treatment Options for Patients Experiencing a Relapse

16.03.2022

Genomic sequencing of tumors from pediatric cancer patients experiencing a relapse enabled 107 patients to receive an appropriate matched therapy that is not the standard of care, according to data from the international clinical trial MAPPYACTS, published in Cancer Discovery, journal of the AACR.

NICE logo

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

16.03.2022

Dostarlimab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

asco logo

Updated CHOICE-01 Data: Toripalimab Improves OS and PFS in NSCLC When Added to First-Line Chemotherapy

15.03.2022

Growing evidence supports the use of toripalimab, a humanized monoclonal antibody directed against PD-1, in combination with standard chemotherapy as first-line treatment of advanced non–small cell lung cancer.

asco logo

More Mature RELATIVITY-047 Data Bolster Potential Use of Combination Relatlimab/Nivolumab in Melanoma

15.03.2022

Dual targeting of the LAG-3 and PD-1 immune checkpoint pathways with relatlimab and nivolumab shows additional advantages in patients with previously untreated advanced melanoma.

ESTRO logo

Randomised Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ

14.03.2022

RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.

esmo logo

FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage NSCLC

14.03.2022

FDA approved nivolumab with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. Efficacy was evaluated in CHECKMATE-816 study.

esmo logo

German National Network Genomic Medicine Suggests a Novel Classification of Atypical EGFR Mutations

11.03.2022

Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors. A multicentre, retrospective analysis performed by the national Network Genomic Medicine in Germany represents the largest available real-world dataset of atypical EGFR mutations.

asco logo

Treating Patients With MSI-H BRAFV600E-Mutated Metastatic Colorectal Cancer

10.03.2022

One-fourth of BRAFV600E metastatic colorectal cancer are microsatellite instability–high (MSI-H), and one-fifth of MSI-H mCRC display the BRAFV600E mutation (MSI-H)—both of which are associated with poor survival and limited response to chemotherapy, with or without targeted therapy.

asco logo

ASCO, Ontario Health Recommendations Address Clinical Management and De-escalation Treatment of the Axilla in Early-Stage Breast Cancer

10.03.2022

The guideline recommends that patients with early-stage breast cancer who are younger than age 70 without significant competing comorbidities should undergo sentinel lymph node biopsy for axillary staging.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Abemaciclib

10.03.2022

EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product abemaciclib. New indication concerns the use in patients with early breast cancer at high risk of recurrence

Journal of Clinical Oncology

ASCO Guideline Update: Adjuvant Therapy for Stage II Colon Cancer

10.03.2022

Recommendations for adjuvant therapy for patients with resected stage II colon cancer. ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria.

esmo logo

Addition of a Live Bacterial Product Enhances the Clinical Outcome in Patients with mRCC Treated with Nivolumab-Ipilimumab Combination

09.03.2022

In a randomised, open-label, single-centre study, a bifidogenic live bacterial product CBM588 augmented response to immune checkpoint inhibitors through modulation of the gut microbiome. CBM588 enhanced the clinical outcome in patients with treatment-naïve metastatic renal cell carcinoma (mRCC) treated with nivolumab–ipilimumab combination.

NCCN logo

NCCN publishes two new NCCN Guidelines for Treating Rare Cancer Types

09.03.2022

The National Comprehensive Cancer Network publishes two new NCCN Guidelines for Malignant Peritoneal Mesothelioma and for Ampullary Adenocarcinoma, to standardize treatment and improve outcomes for these rare tumor types; also reaches milestone expanding library of NCCN Chemotherapy Order Templates.

PTChO logo

Cykl „Advances in diagnostics and therapy of melanoma and other skin cancers”

08.03.2022

PTChO zaprasza na cykl webinariów „Advances in diagnostics and therapy of melanoma and other skin cancers”. Cykl składa się z trzech spotkań online w następujących terminach: 24.03.2022, 28.04.2022, 09.06.2022. Więcej informacji o webinarium znajduje się na stronie https://melanoma.viamedica.pl.

esmo logo

No Impact on Survival from Dose Reduction and Interruption for the Management of Olaparib Associated Adverse Events

08.03.2022

In the SOLO2 study of olaparib, dose reductions and interruptions were used to manage adverse events. However, patients who underwent protocol recommended dose alterations related to adverse events did not have inferior survival outcomes compared to those who received at or very close to the recommended dose.

NICE logo

NICE draft guidance does not recommend pembrolizumab plus chemotherapy for triple negative breast cancer

08.03.2022

The evidence showed that pembrolizumab plus chemotherapy is more effective than paclitaxel or nab-paclitaxel, although the long-term benefit is uncertain. In addition, there was no trial data directly comparing pembrolizumab plus chemotherapy with atezolizumab plus chemotherapy, another targeted treatment which NICE already recommends.

ESTRO logo

Side Effects 15 Years After Lymph Node Irradiation in Breast Cancer

07.03.2022

The incidence of late pulmonary side effects was statistically significantly higher after IM-MS lymph node irradiation, as were some of the cardiac events, without a difference between left- and right-sided treatments. Absolute rates and differences were very low, without increased non-breast cancer-related mortality, even before introducing heart-sparing techniques.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Nivolumab

07.03.2022

New indications concern the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma and the adjuvant treatment of muscle invasive urothelial carcinoma.

esmo logo

Humoral Response to the Third Dose of the mRNA-based COVID-19 Vaccine in a Large Cohort of Patients with Cancer

04.03.2022

In a letter to editor published on 21 February 2022 in the Annals of Oncology, Dr. Vincenzo Di Noia and colleagues described the serological response to the third dose of the BNT162b2 mRNA COVID-19 vaccine in a large cohort of patients with cancer. Most patients were on active anticancer treatment during the 28 days before the administration.

NICE logo

People can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund

03.03.2022

An innovative life-extending drug - sotorasib - for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.

asco logo

With Increasingly Effective HER2-Targeted Agents, Does Carboplatin Have Utility in HER2-Positive Breast Cancer?

03.03.2022

Several trials have evaluated strategies for sparing chemotherapy in patients with nonmetastatic HER2-positive breast cancer, including the use of trastuzumab, pertuzumab, and ado-trastuzumab emtansine. For patients with more advanced tumors, neoadjuvant regimens may be used to achieve a pathologic complete response.

asco logo

Cytopenias After CAR T-Cell Therapy: A Common and Cumbersome Challenge

03.03.2022

Hematologic toxicity associated with chimeric antigen receptor (CAR) T-cell therapy remains a major challenge for safe administration of CAR T-cell products for relapsed/refractory malignancies.

esmo logo

Lung Metastases, Cytoreductive Nephrectomy and Favourable Risk Group Associated with a Higher Probability of Response to First-Line Combination Therapy in mRCC

00.03.2022

In an analysis of 1,084 patients with metastatic renal cell carcinoma performed by the international metastatic renal cell database consortium, the presence of lung metastases, cytoreductive nephrectomy performed after diagnosis of metastatic disease and before first-line therapy and better IMDC risk group were associated with a higher probability of response to first-line immunotherapy combination regimens.

PTChO logo

Plastyka piersi – prepektoralne rekonstrukcje wyniosłości piersiowe

03.03.2022

PTChO serdecznie zaprasza na praktyczny kurs kadawerowy „Plastyka piersi – prepektoralne rekonstrukcje wyniosłości piersiowej". 25 marca 2022 r. (piątek): Centrum Edukacji Medycznej, Warszawa. Kierownik naukowy: prof. dr hab. n. med. Agnieszka Kołacińska – Wow, Instruktor: prof. dr hab. n. med. Dawid Murawa.

asco logo

Evaluating the Current Role of PSMA PET: Utility, Availability, and Challenges

02.03.2022

PSMA PET imaging may prove useful in the diagnosis and treatment of metastatic castration-resistant prostate cancer by assessing a patient's response to therapy and by defining the phenotype of disease.

asco logo

Advances in Adjuvant Therapy for Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Pembrolizumab Shows Promise

02.03.2022

Adjuvant therapy in renal cell carcinoma (RCC) is an area of investigation motivated by the alarming statistic that 30% of patients with localized disease will experience metastatic recurrence after nephrectomy.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Stimufend

02.03.2022

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product pegfilgrastim (Stimufend), intended to reduce the duration of neutropenia and the incidence of febrile neutropenia after cytotoxic chemotherapy.

esmo logo

Adding Darolutamide to ADT and Docetaxel Prolongs Overall Survival in Patients with Metastatic, Hormone-Sensitive Prostate Cancer

01.03.2022

In phase III ARASENS study that involved patients with metastatic, hormone-sensitive prostate cancer, overall survival (OS) was significantly longer among patients who received darolutamide plus androgen-deprivation therapy (ADT) and docetaxel than among those who received placebo plus ADT and docetaxel.

Journal of Clinical Oncology

ASCO-OH (CCO) Guideline Update: Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

01.03.2022

Adjuvant bisphosphonate therapy should be discussed with all postmenopausal patients (natural or therapy-induced) with primary breast cancer, irrespective of hormone receptor status and human epidermal growth factor receptor 2 status, who are candidates to receive adjuvant systemic therapy.

esmo logo

Cancer Mortality Predictions for the 10 Major Causes of Cancer Mortality and Total Cancer in 2022 in the European Union

25.02.2022

A report published in March 2022 issue of the Annals of Oncology confirms predicted declining mortality rates for most major cancers and total cancers in both sexes in European Union (EU) estimated at 6% for men and 4% for women over the past 5 years.

NICE logo

NICE draft guidance recommends tucatinib for advanced breast cancer

25.02.2022

Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.

PTGO logo

Już wkrótce – Nowe kompleksowe rekomendacje skriningu raka szyjki macicy w Polsce 2022

24.02.2022

Wytyczne postępowania z wynikami testów skriningowych w HPV-zależnej strategii prewencji wtórnej raka szyjki macicy. Konsensus PTGiP, PTGO, PTMR, PTP oraz PTKiPSM 2022 to podjęte przez wskazane towarzystwa naukowe wyzwanie wypracowania optymalnego dla polskich warunków opartego o EBM konsensusu skriningu rsm na wszystkich jego etapach w strategii HPV-zależnej.

esmo logo

In NeoTRIP, Atezolizumab with Neoadjuvant Carboplatin/Nab-Paclitaxel was Feasible in TNBC, but Led to Non-Significant pCR Increase

24.02.2022

The study primary endpoint is event-free survival, and lack of improvement in pathologic complete response may be misleading as to the impact of atezolizumab on long-term efficacy in high-risk triple-negative breast cancer.

NICE logo

Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS

24.02.2022

Taken as a once-a-day capsule, niraparib is recommended for people whose cancer has relapsed and have a specific mutation in their cancer known as a BRCA mutation and who have had two courses of platinum-based chemotherapy.

ESTRO logo

Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer

24.02.2022

Postoperative Adjuvant Radiation in Cervical Cancer (PARCER), a phase III randomised trial, compared late toxicity after image-guided intensity-modulated radiotherapy (IG-IMRT) with three-dimensional conformal radiation therapy (3D-CRT) in women with cervical cancer undergoing postoperative radiation.

asco logo

How to Incorporate Tucatinib Into HER2-Positive Metastatic Breast Cancer Treatment

23.02.2022

Tucatinib was studied in combination with trastuzumab and capecitabine in patients with metastatic HER2-positive breast cancer in a phase 3 randomized clinical trial (HER2CLIMB); the tucatinib combination showed efficacy over the control population, who were treated with trastuzumab, capecitabine, and placebo.

asco logo

Adjuvant Therapy in Non–Small Cell Lung Cancer: Closer to Cure or Just Delaying Progression?

23.02.2022

Non–small cell lung cancer (NSCLC) constitutes 80% to 85% of all lung cancers. Surgical resection offers the best opportunity for survival in the early stages, yet a high risk of developing recurrent disease remains.

asco logo

Chemoimmunotherapy: Still the Standard of Care for Metastatic Triple-Negative Breast Cancer

23.02.2022

Immune checkpoint inhibitors (ICIs) have substantially impacted treatment outcomes for patients with triple-negative breast cancer (TNBC) and have led to a paradigm shift of testing triple-negative tumors for PD-L1 when considering chemoimmunotherapy for metastatic disease.

ASTRO logo

Mid-treatment imaging can be used to de-escalate therapy for oropharynx cancer, leading to fewer side effects

23.02.2022

A new phase II trial finds that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.

ASTRO logo

Tumor tissue modified viral (TTMV)-HPV DNA biomarker test predicts recurrence of HPV-driven oropharynx cancer after treatment

23.02.2022

A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicate that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.

esmo logo

Late Breast Cancer Recurrence Less Aggressive and Associated with Better Prognosis Compared to Early Recurrence

23.02.2022

In a first large population-based cohort study to investigate the impact of late breast cancer recurrence on mortality, to evaluate prognostic factors, and to compare survival after late recurrence with survival after early recurrence, women who developed late recurrence had better prognosis compared with those with early recurrence.

esmo logo

Pemigatinib, a Selective FGFR 1–3 Inhibitor Is Safe, Tolerable and Demonstrates Pharmacologic, Clinical Activity

22.02.2022

Pemigatinib, a potent and selective FGFR 1–3 inhibitor, was safe and tolerable and demonstrated pharmacologic/clinical activity in cholangiocarcinoma, urothelial carcinoma, recurrent pilocytic astrocytoma, head and neck, pancreatic, gallbladder, uterine, and non-small cell lung cancers.

esmo logo

Older Patients with Cancer and High-Risk Geriatric Profiles at Greater Risk for Death and Other Adverse Sequelae of COVID-19

21.02.2022

In a large study of 5671 older adults with COVID-19 and cancer, performed by the COVID-19 and Cancer Consortium (CCC19), the CCC19 geriatric risk index was associated with poorer outcomes, including clinical complications, hospitalisation, and mortality.

ESTRO logo

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

21.02.2022

This secondary analysis of a randomised clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority.

esmo logo

Frontline Treatment with Brentuximab Vedotin Plus CHP Provides Clinically Meaningful Improvement in Survival Compared to CHOP in Patients with PTCL

18.02.2022

In 5-year update of ECHELON-2 study, frontline treatment of patients with peripheral T-cell lymphoma (PTCL) with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone continues to provide clinically meaningful improvement in progression-free survival and overall survival.

asco logo

ASCO Provisional Clinical Opinion Offers Guidance for Using and Interpreting Genomic Testing in Patients With Advanced Cancer

18.02.2022

Somatic genomic testing should be a routine part of clinical care for many patients with metastatic or advanced solid tumors, according to a new ASCO provisional clinical opinion. As reported in the Journal of Clinical Oncology, the Expert Panel found that genomic testing in oncology practice has evolved to the point where a wide spectrum of patients with cancer may benefit.

AACR logo

T-cell Responses May Help Predict Protection Against SARS-CoV-2 Infection in Individuals With and Without Cancer

18.02.2022

T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers, according to results from a study published in Cancer Discovery.

PTOK logo

Nowotwory złośliwe w Polsce w 2019 roku

17.02.2022

Ukazała się nowa publikacja Krajowego Rejestru Nowotworów oraz Narodowego Instytutu Onkologii – Nowotwory złośliwe w Polsce w 2019 roku.

PTGO logo

Rola ultrasonografii w raku endometrium – webinar

17.02.2022

PTGO po raz drugi zaprasza na spotkanie z cyklu „Spotkania z Ekspertem AKADEMII GINEKOLOGA ONKOLOGA”. Tym razem naszym gościem będzie prezes Polskiego Towarzystwa Ginekologii Onkologicznej, ekspert w dziedzinie diagnostyki ultrasonograficznej, profesor Włodzimierz Sawicki.

ESTRO logo

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS)

17.02.2022

Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended.

asco logo

Adjuvant Pembrolizumab After Nephrectomy in Renal Cell Carcinoma: Embracing the Promises and Acknowledging the Uncertainties

17.02.2022

The positive interim analysis of the KEYNOTE-564 trial led to FDA approval of pembrolizumab in the adjuvant setting for patients with renal cell carcinoma whose risk of experiencing recurrence is intermediate-high or high after nephrectomy; the approval also includes patients with metastatic RCC following nephrectomy and resection of all metastatic lesions.

esmo logo

Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After First-Line Platinum-Containing Chemotherapy

16.02.2022

Treatment with cemiplimab in a phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study led to significantly longer overall survival (OS) than chemotherapy among patients with recurrent cervical cancer who had had disease progression after first-line platinum-containing chemotherapy.

asco logo

Recommendations for Baseline Pulmonary Function Tests Prior to Trastuzumab Deruxtecan

16.02.2022

Novel targeted therapies, such as trastuzumab deruxtecan, can be associated with rare adverse events including interstitial lung disease. In cancer therapies with the potential for pulmonary toxicity, pulmonary function tests provide an objective measure for baseline and longitudinal assessment.

esmo logo

Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves Event-Free Survival in High-Risk, Early TNBC

15.02.2022

In a phase III study, neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab resulted in a significant improvement, as compared with neoadjuvant chemotherapy alone, in event-free survival among patients with previously untreated stage II or III triple-negative breast cancer.

ESTRO logo

Association of Delayed Surgery With Oncologic Long-term Outcomes in Patients With Locally Advanced Rectal Cancer Not Responding to Preoperative Chemoradiation

14.02.2022

In this cohort study, a longer interval before surgery after completing neoadjuvant CRT was associated with worse overall and disease-free survival in tumours with a poor pathological response to preoperative CRT. Based on these findings, patients who do not respond well to CRT should be identified early after the end of CRT and undergo surgery without delay.

esmo logo

Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation in Refractory Setting

14.02.2022

The NCI-MATCH is a tumour-agnostic platform that enrols patients on the basis of matching genomic alterations. The NCI-MATCH ECOG-ACRIN study (EAY131) subprotocol Z1F evaluated copanlisib, specific phosphoinositide 3-kinase (PI3K) inhibitor, in patients with PIK3CA mutations.

ESSO logo

WHO short guide to cancer screening

11.02.2022

This short guide is designed to be a quick reference that contains the important ideas about cancer screening. Readers should refer to other publications for comprehensive discussion and detailed guidance on cancer screening programmes.

esmo logo

Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment Modalities

11.02.2022

Examination of adverse events by sex using combined data from 23,296 patients enrolled in 202 phase II and III clinical studies conducted by SWOG between 1989 and 2019 revealed greater severity of both symptomatic adverse events and haematologic adverse events in women across multiple treatment modalities, indicating that broad-based sex differences exist.

Journal of Clinical Oncology

ASCO-SNO-ASTRO Guideline: Treatment for Brain Metastases

10.02.2022

Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used.

NICE logo

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

09.02.2022

Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if their tumours express PD‑L1 with a tumour proportion score of 0% to 49%, their tumours express PD‑L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention, it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses.

asco logo

Overcoming Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Is There a Role for VEGF Inhibitor Treatment?

09.02.2022

Anti–PD-1 and VEGFi combinations appear to be encouraging strategies for overcoming primary and acquired resistance to immune checkpoint inhibitors. Leading the pack is the quadruple combination of atezolizumab / bevacizumab / carboplatin / paclitaxel (ABCP), approved for first-line treatment of metastatic non–small lung cancer.

esmo logo

With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide Long-Term Survival Benefit Over Chemotherapy in Unresectable Malignant Pleural Mesothelioma

09.02.2022

With a follow-up of at least 3 years, the results from the CheckMate 743 represent the first long-term survival data in a phase III study evaluating first-line immune checkpoint inhibitor (ICI) in patients with unresectable malignant pleural mesothelioma.

esmo logo

Robust and Sustained Survival Benefit with Consolidation Durvalumab After Concurrent Chemoradiotherapy for Unresectable, Stage III NSCLC

08.02.2022

Updated survival analyses from the PACIFIC study demonstrate robust and sustained survival benefit with durvalumab in patients with unresectable, stage III non–small-cell lung cancer (NSCLC) and no disease progression after concurrent chemoradiotherapy.

NICE logo

Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund

08.02.2022

NICE has published its final appraisal document on dostarlimab, an immunotherapy treatment which could benefit 124 people a year in England as a second-line treatment for endometrial cancer with high microsatellite instability or mismatch repair deficiency.

NCCN logo

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

07.02.2022

Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients.

esmo logo

FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma

07.02.2022

FDA approved tebentafusp-tebn, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Efficacy was evaluated in IMCgp100-202 (NCT03070392), a randomised, open-label, multicentre study of 378 patients with metastatic uveal melanoma.

ESTRO logo

Nomogram for Predicting the Prognoses of Patients With Pancreatic Head Cancer After Pancreaticoduodenectomy

07.02.2022

There are many factors affecting the prognosis in pancreatic head cancer after pancreaticoduodenectomy. Postoperative radiotherapy and chemotherapy can improve patient survival. These still need to be further validated in the future.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel

04.02.2022

EMA adopted a positive opinion for the medicinal product lisocabtagene maraleucel, intended for the treatment of adults with relapsed or refractory diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma and follicular lymphoma grade 3B, after at least two previous lines of treatments.

esmo logo

Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable for HER2-Mutated, Pretreated Advanced NSCLC

03.02.2022

For the first time in patients with HER2-mutated advanced non-small cell lung cancer, the results of treatment with the combination of pertuzumab, trastuzumab and docetaxel, which is widely used for the management of HER2-positive breast cancer have been extrapolated in the IFCT-1703 R2D2 study.

esmo logo

Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of Cancer

02.02.2022

Besides female breast and ovarian cancers, BRCA1/2 pathogenic variants are associated with increased risks of breast cancer in men, and pancreatic and stomach cancers in both sexes, and BRCA2 carriers are at elevated prostate cancer risk. No associations were found with risks of other cancers.

NICE logo

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma

02.02.2022

Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of completely resected stage 3 melanoma with lymph node involvement in adults.

asco logo

Checkpoint Inhibitors for All or Only for High PD-L1 Expression: Exploring First-Line Therapy for Patients With Metastatic Gastroesophageal Malignancies

02.02.2022

Recent clinical trials of immune checkpoint inhibitor (ICI) therapy suggest the practice-changing potential of these agents for patients with advanced gastroesophageal malignancies.

asco logo

The Role of Adjuvant Therapy in Muscle-Invasive Bladder Cancer: Implications Across the Disease Spectrum

02.02.2022

Postoperative administration of immune checkpoint inhibitors is being studied as a less toxic treatment approach for muscle-invasive urinary bladder cancer. CheckMate-274 found a statistically significant difference in median disease-free survival for nivolumab vs placebo.

asco logo

Exploring Nonsurgical Salvage Options for Bacillus Calmette-Guérin–Unresponsive Carcinoma In Situ of the Bladder: An Evolving Algorithm

02.02.2022

Many trials—accruing and soon to open—are likely to change the management algorithm over the coming decade to incorporate organ-sparing alternatives for patients with bacillus Calmette-Guérin (BCG)–unresponsive carcinoma in situ (CIS) of the bladder.

Journal of Clinical Oncology

ASCO-SNO Guideline: Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

01.02.2022

ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature to provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. Fifty-nine randomized trials focusing on therapeutic management were identified.

estro logo

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

31.01.2022

Progression-free and overall survival were significantly longer with pembrolizumab than with placebo among patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab.

esmo logo

Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in BRAF V600E–Mutated Anaplastic Thyroid Cancer

31.01.2022

Updated analysis of the anaplastic thyroid cancer cohort from an open-label, non- randomised phase II Rare Oncology Agnostic Research study confirms earlier observations that the combination of dabrafenib plus trametinib has meaningful clinical activity in patients with BRAF V600E–mutated advanced or metastatic anaplastic thyroid cancer.

esmo logo

Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated HER2-Mutated Metastatic NSCLC

28.01.2022

In a phase II DESTINY-Lung01 study, treatment with trastuzumab deruxtecan showed durable anticancer activity in 91 patients with HER2-mutated non-small cell lung cancer.

EORTC logo

Promising results for the ultra-low risk patient group in latest MINDACT analysis

27.01.2022

The MINDACT (EORTC 10041/BIG3-04) study, a multicentre, randomised phase 3 clinical trial, aims to identify those women with early-stage breast cancer who can be spared chemotherapy after surgery through the use of a genomic and clinical risk assessment.

asco logo

Benefit of First-Line Pembrolizumab Plus Chemotherapy in Esophageal Cancer Bolstered by Longer-Term Efficacy, Safety, and QOL

27.01.2022

Updated KEYNOTE-590 data continue to show overall and progression-free survival benefits in all key subgroups of interest, along with manageable safety and stable quality of life. These findings reinforce the status of pembrolizumab plus chemotherapy as a first-line standard of care for advanced esophageal cancer.

asco logo

Adjuvant Therapy in Localized Renal Cancer: Can One Study Change the Standard of Care?

27.01.2022

Although surgical resection is the traditional treatment for localized renal cell carcinoma, sunitinib and pembrolizumab have each demonstrated disease-free survival benefit in the adjuvant setting, in the S-TRAC and KEYNOTE-564 trials, respectively.

asco logo

Optimizing Immunotherapy Combinations in Mismatch Repair–Proficient/Microsatellite-Stable Metastatic Colorectal Cancer

27.01.2022

The greatest breakthrough in the treatment of metastatic colorectal cancer recently has been the use of ICIs for deficient mismatch repair – status tumors; ICIs, such as pembrolizumab or combination nivolumab/ipilimumab, can provide prolonged disease control in some patients.

asco logo

Dual-Immunotherapy STRIDE Regimen Likely to Become a New First-Line Option for Patients With Advanced Hepatocellular Carcinoma

27.01.2022

The HIMALAYA trial demonstrated that a single priming dose of tremelimumab plus once-monthly durvalumab significantly improved overall survival compared with sorafenib for patients with advanced unresectable hepatocellular carcinoma, meeting the primary endpoint.

asco logo

First-Line Lenvatinib Plus TACE Improves Efficacy Outcomes Compared With Lenvatinib Monotherapy in Advanced Hepatocellular Carcinoma

27.01.2022

Phase 3 LAUNCH trial shows that adding TACE to lenvatinib improves efficacy outcomes in previously untreated patients with Barcelona Clinic Liver Cancer stage C Hepatocellular Carcinoma.

asco logo

Presence of ctDNA Following CRC Resection Heralds Increased Relapse Risk and Characterizes Adjuvant Chemotherapy Benefits

27.01.2022

GALAXY, the largest study evaluating molecular residual disease in colorectal cancer (CRC), demonstrates that tracking circulating tumor DNA after surgery serves as a strong prognostic marker and may provide the opportunity to optimize clinical outcomes for patients with CRC

esmo logo

Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAdverseEvents

27.01.2022

In patients with melanoma who are treated with immune checkpoint inhibitors, clonally diverse and activated memory CD4-positive T cells at baseline are associated with the development of severe immune-related adverse events (irAEs), irrespective of the affected organ system.

esmo logo

Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab Than with Chemotherapy in Advanced Endometrial Cancer

26.01.2022

Findings from the Study 309–KEYNOTE-775 among patients who had disease progression after the receipt of previous systemic platinum-based therapy.

ECO logo

Ensuring Equal Access to All - Cancer in Women: Europe’s Beating Cancer Plan Event

26.01.2022

On 2 February, Stella Kyriakides, European Commissioner for Health and Food Safety, will host a hybrid event entitled “Ensuring equal access to all: Cancer in Women - Europe’s Beating Cancer Plan” to raise awareness of cancer in women and to announce the latest actions under the EU’s Cancer Plan.

esmo logo

A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival in Unselected Patients with mCRPC Whose Disease Progressed on Abiraterone

25.01.2022

In the phase III IMbassador 250 study, a combination of an immune checkpoint inhibitor atezolizumab with a second-generation oral androgen receptor antagonist enzalutamide did not improve survival over enzalutamide alone in patients with metastatic castration-resistant prostate cancer whose disease progressed on abiraterone.

esmo logo

Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer

24.01.2022

AI algorithms have shown promise for grading prostate cancer, specifically in prostatectomy samples and biopsies, and by assisting pathologists in the microscopic reviews, but they are susceptible to various biases in their development and validation.

estro logo

The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases

24.01.2022

Selected patients with brain metastases (BM) are candidates for radiotherapy. A lactatogenic metabolism, common in BM, has been associated with radioresistance. We demonstrated that BM express nitric oxide (NO) synthase 2 and that administration of its substrate L-arginine decreases tumour lactate in BM patients.

asco logo

TOPAZ-1: Durvalumab Plus Gemcitabine and Cisplatin Could Become New First-Line Standard of Care for Advanced Biliary Tract Cancer

21.01.2022

TOPAZ-1, the first global phase 3 study to evaluate use of immunotherapy in the first-line setting in advanced biliary tract cancers, demonstrated that adding the PD-L1 inhibitor durvalumab to gemcitabine and cisplatin—the current first-line standard of care—significantly improves overall survival and other efficacy outcomes without exacerbating toxicity.

esmo logo

Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers

21.01.2022

Incidence of regional and distant metastasis is higher in paediatric patients compared with adults with differentiated thyroid cancer. Study shows that RET and NTRK fusions are the most prevalent genetic alterations in paediatric differentiated thyroid cancer.

ESSO logo

Textbook of Pancreatic Cancer: Principles & Practice of Surgical Oncology

21.01.2022

This textbook provides a practically applicable resource for understanding the surgical oncology management of pancreatic cancer. It discusses relevant aspects of anatomy and pathophysiology along with the latest diagnostic techniques. Insightful descriptions are then provided detailing how to perform critical surgical procedures when treating these patients.

AACR logo

Combination Therapies May Improve Outcomes Due to Independent, Rather Than Synergistic or Additive, Drug Action

20.01.2022

Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a retrospective analysis published in Clinical Cancer Research.

asco logo

Expanded CheckMate-649 Data Confirm the Benefit of First-Line Nivolumab Plus Chemotherapy in Metastatic Esophagogastric Cancer

20.01.2022

Long-term efficacy and safety data for first-line nivolumab plus chemotherapy bolster its use as standard treatment in patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.

asco logo

The Evolving Landscape in the Treatment of Stage II Testicular Seminoma

20.01.2022

Although the established treatments for stage II testicular seminoma have an excellent cure rate, the long-term toxicities and increased risk for second primary cancers associated with these approaches are a concern.

asco logo

Paclitaxel/Carboplatin Not Inferior to Paclitaxel/Ifosfamide in Uterine Carcinosarcoma

20.01.2022

Patients with uterine carcinosarcoma and ovarian carcinosarcoma have very poor outcomes and more efficacious treatments are needed. The objective of the phase 3 randomized noninferiority GOG-0261 trial was to determine if the survival of patients with UCS or OCS receiving paclitaxel/carboplatin was inferior to patients who were treated with paclitaxel/ifosfamide.

esmo logo

A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma

20.01.2022

COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in this phase III study of spartalizumab in combination with dabrafenib and trametinib versus placebo in combination with dabrafenib and trametinib.

Journal of Clinical Oncology

ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update: Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer

20.01.2022

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual.

PTChO logo

Dostęp do zasobów polskojęzycznej wersji pisma Nowotwory

19.01.2022

Z radością informujemy, że od 1 stycznia 2022 dostęp do zasobów polskojęzycznej wersji pisma Nowotwory. Journal of Oncology, które dotychczas ukazywało się drukiem pod tytułem Nowotwory – Biuletyn Polskiego Towarzystwa Onkologicznego, zostanie otwarty dla wszystkich.

Annals of Oncology logo

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

19.01.2022

This ESMO Clinical Practice Guideline provides key recommendations on the management of testicular seminoma and non-seminoma. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe. Key treatment recommendations are provided.

NICE logo

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

19.01.2022

Osimertinib is recommended for use as adjuvant treatment after complete tumour resection in adults with stage 1b to 3a non‑small‑cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity.

esmo logo

Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant OS Improvement in Patients with HER2-positive Metastatic Breast Cancer

19.01.2022

Continued overall survival benefit and tolerability of tucatinib in combination with trastuzumab and capecitabine, demonstrated in a final analysis of the HER2CLIMB study, augments data from the primary analysis and further supports the use of this combination in patients with previously treated HER2-positive metastatic breast cancer after progression on two HER2-targeted therapies.

asco logo

Targeted Therapy in Metastatic Non–Small Cell Lung Cancer: Recent Updates and Controversies

19.01.2022

Targeted therapies have dramatically improved treatment outcomes for patients with molecularly defined subsets of NSCLC, and the FDA continues to rapidly approve new therapies for NSCLC mutations/fusions in the metastatic setting.

asco logo

ASCO and Ontario Health Provide Updated Recommendations on Using Adjuvant Bone-Modifying Treatments in Nonmetastatic Breast Cancer

19.01.2022

An update to a joint guideline from Cancer Care Ontario and ASCO provides revised recommendations for the use of adjuvant bone-modifying agents for patients with nonmetastatic breast cancer with the overarching goal of improving relapse and survival rates.

esmo logo

Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early Breast Cancer

18.01.2022

The Finland Capecitabine Trial (FinXX) researchers found that addition of capecitabine to a taxane-anthracycline chemotherapy backbone improved overall survival in patients with early breast cancer during a median follow-up for 15 years after the date of random assignment.

asco logo

Neoadjuvant Nivolumab Plus Ipilimumab Shows Promising Activity in Early-Stage MSI/dMMR Esophagogastric Junction and Gastric Adenocarcinoma

18.01.2022

Neoadjuvant treatment with nivolumab and ipilimumab in patients with MSI/dMMR esophagogastric junction and gastric adenocarcinoma yielded a pathologic complete response rate of 59%—far higher than the 10% pCR rate expected with cytotoxic chemotherapy.

asco logo

Encouraging Results for Adagrasib Observed in Patients With KRAS G12C-Mutated GI Malignancies

18.01.2022

Adagrasib monotherapy demonstrates encouraging activity in patients with a variety of advanced KRAS G12C-mutated gastrointestinal malignancies. Notably, in patients with pancreatic ductal adenocarcinoma, single-agent adagrasib confers a 50% partial response rate and a 100% disease control rate.

asco logo

Patients With CRC and Sarcopenia Have More Treatment Toxicity Associated With 5-FU-Based Regimens

18.01.2022

Patients with metastatic CRC who had sarcopenia at baseline were more likely to experience severe neutropenia during first-line FOLFOX or FOLFIRI. The findings also suggest that lean body mass may be an important factor in determining 5-FU dosing.

asco logo

Large Analysis Illustrates Advantages of Using Liquid Biopsy to Identify, Manage Disease in Patients With Advanced MSI-H GI Cancers

18.01.2022

A large-scale analysis suggests that liquid biopsy performs about as well as tissue biopsy for identifying MSI-H in patients with advanced GI cancers and can be used successfully to guide treatment with immune checkpoint inhibitors.

PTGO logo

Nowe trendy w profilaktyce raka szyjki macicy – webinar

17.01.2022

Z okazji Europejskiego Tygodnia Profilaktyki Raka Szyjki Macicy PTGO chce przypomnieć Państwu obecne możliwości i wytyczne dotyczące pierwotnej i wtórnej profilaktyki w raku szyjki macicy. Zapraszamy na spotkanie 27 stycznia z Ekspertami w tej dziedzinie, Profesorem Janem Kotarskim i Profesorem Robertem Jachem.

PTU logo

9. Sympozjum Sekcji Urologii Onkologicznej PTU

17.01.2022

Zarząd Sekcji Urologii Onkologicznej (SUO) Polskiego Towarzystwa Urologicznego zaprasza do wzięcia udziału w 9. Sympozjum Sekcji Urologii Onkologicznej, które odbędzie się w Warszawie w dniach 4-5 marca 2022 r. Celem spotkania jest przedstawienie wyników najnowszych badań i osiągnięć w zakresie urologii, omawianych podczas zbliżającego się spotkania European Section of Oncological Urology – ESOU.

ESTRO logo

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma

17.01.2022

The role of radiotherapy in metastatic renal cell carcinoma is controversial. We prospectively tested the feasibility and efficacy of radiotherapy to defer systemic therapy for patients with oligometastatic renal cell carcinoma.

esmo logo

Impressive Responses to PD-1 Blockade in a Large Cohort of Children and Young Adults with Recurrent/Progressive Germline DNA Replication Repair-Deficient Cancers

17.01.2022

Study reveals impressive responses to PD-1 blockade and an associated improved survival for relapsed/refractory hypermutated cancers in children and young adults with germline DNA replication repair deficiency.

esmo logo

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

14.01.2022

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide in patients with uterine carcinosarcoma.

asco logo

Fulfilling the Potential of HER2 Therapies for Patients With Metastatic Colorectal Cancer

13.01.2022

Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality, and amplification of the HER2 gene is the latest molecular subset to be therapeutically targetable in this disease.

esmo logo

Pembrolizumab Demonstrates Robust and Durable Antitumour Activity in Patients with Previously Treated Advanced MSI-H/dMMR Endometrial Cancer

13.01.2022

Findings from the KEYNOTE-158 study support the use of pembrolizumab as a treatment option for patients with advanced MSI-H/dMMR endometrial cancer with treatment failure on prior therapy.

ASTRO logo

ASTRO issues clinical guideline on external beam radiation therapy for primary liver cancers

12.01.2022

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).

NICE logo

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer

12.01.2022

Selpercatinib is recommended for use as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy or both.

NCCN logo

New Research in JNCCN Raises Awareness of the Dangers of Septic Shock in Blood Cancer Patients

12.01.2022

Study led by MD Anderson Cancer Center found more than two-thirds of patients with blood cancer who experienced septic shock died within 28 days.

esmo logo

Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer

12.01.2022

Patients with cancer who develop breakthrough COVID-19 remain at risk of severe outcomes despite full vaccination.

esmo logo

Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate Cancer with Combination Treatment Than with ADT Alone

11.01.2022

Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol.

EORTC logo

Pembrolizumab Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

10.01.2022

Merck known as MSD outside the US and Canada, EORTC and ETOP announced that the Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, investigating pembrolizumab anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.

ESTRO logo

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

10.01.2022

Among premenopausal women with one to three positive lymph nodes and a recurrence score of 25 or lower, those who received chemoendocrine therapy had longer invasive disease–free survival and distant relapse–free survival than those who received endocrine-only therapy.

esmo logo

Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated Metastatic or Unresectable Melanoma

10.01.2022

A phase II/III, RELATIVITY-047 study evaluated dual inhibition of LAG-3 and PD-1 using a new combination of LAG-3–blocking antibody relatlimab and PD-1–blocking antibody nivolumab, as compared with nivolumab alone.

baner konferencji Choroby jelit grubego

II Konferencja Choroby jelit grubego

10.01.2022

Zapraszamy na kolejną edycję konferencji poświęconej chorobom jelita grubego. Konferencja odbędzie się w dniach 21-22 kwietnia 2022 roku w Krakowie. W trakcie wydarzenia poruszone zostaną aktualne tematy dotyczące nowotworów jelita grubego i technik endoskopowych.

asco logo

New Treatment Options for Hepatocellular Carcinoma Raises Questions for Optimal Sequencing of Therapies

07.01.2022

Treatment options have greatly expanded for patients with advanced hepatocellular carcinoma, with benefits seen with tyrosine kinase inhibitors, checkpoint inhibitors, and antiangiogenic antibodies.

Viamedica logo

Nowości w leczeniu raka piersi po SABCS 2021

07.01.2022

W ramach webinaru zostaną przedstawione najnowsze doniesienia, dotyczące postępowania u chorych na nowotwory piersi, ze szczególnym uwzględnieniem tych z konferencji „San Antonio Breast Cancer Symposium 2021”. Webinar odbędzie się 14 stycznia 2022 roku.

asco logo

Current Trends in the Treatment of Locally Advanced Rectal Cancer

06.01.2022

Total neoadjuvant therapy (TNT), which is full chemotherapy and chemoradiation in the preoperative period, is increasingly viewed by clinicians as the treatment of first resort, perhaps even the standard of care. No single protocol for TNT exists, making treatment selection challenging.

asco logo

Combining Immunotherapy With Neoadjuvant Chemoradiation in the Treatment of Locally Advanced, Resectable Esophago-Gastric Cancers

05.01.2022

The role of immunotherapy in the treatment of locally advanced, resectable esophago-gastric cancers is expanding, with recent ASCO guidelines advocating the selective utilization of immune checkpoint inhibition in the adjuvant setting after trimodality therapy.

asco logo

Exploring Emerging Treatment Targets for Multiple Myeloma

05.01.2022

The therapeutic landscape for patients with relapsed/refractory multiple myeloma (MM) continues to evolve with the introduction of new targets and advances in cellular therapy and immunology.

NCCN logo

Protecting People with Cancer from COVID-19: New Recommendations from Cancer Guidelines Organization

04.01.2022

National Comprehensive Cancer Network published significant updates to the expert consensus recommendations on vaccination and pre-exposure prophylaxis of COVID-19 in people with cancer.

ESTRO logo

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

03.01.2022

Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer.

esmo logo

EMA Recommends Extension of Indications for Tegafur

24.12.2021

New indication concerns the treatment of patients with metastatic colorectal cancer for whom due to toxicity is not possible to continue treatment with another fluoropyrimidine.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Tepotinib

23.12.2021

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product tepotinib, intended for the treatment of patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.

asco logo

Guideline Update Highlights the Importance of Shared Decision - Regarding the Use of Adjuvant Therapy in Stage II Colon Cancer

23.12.2021

ASCO has published updated guidance on the use of adjuvant therapy in the management of stage II colon cancer, providing clinicians with a newer evidence-based framework that can be used in shared decision-making with patients.

asco logo

Use of Consolidation Durvalumab and Adjuvant Osimertinib Among Key Recommendations in New ASCO Guideline on Stage III NSCLC Treatment

23.12.2021

A new ASCO guideline provides key recommendations for the evaluation and management of stage III non–small cell lung cancer (NSCLC). Recommendations made by the ASCO Expert Panel cover evaluation and staging of NSCLC, neoadjuvant and adjuvant therapy, and the management of unresectable disease.

esmo logo

Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line Treatment for Advanced Hepatocellular Carcinoma

22.12.2021

In CheckMate 459 study nivolumab monotherapy did not significantly prolong overall survival (OS) compared with sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma. However, nivolumab showed durable clinical activity in terms of response frequency and durability.

asco logo

PSMA: The Next Frontier in Prostate Cancer Theranostics

22.12.2021

2021 was an exciting year for advancements in prostate cancer with novel diagnostic imaging, particularly prostate-specific membrane antigen (PSMA) and now the first theranostic targeted therapy.

asco logo

Treating Patients With T1 Bladder Cancer: Timely Cystectomy Should Not Be Forgotten

22.12.2021

The benefits of timely cystectomy must be weighed against the risks—most important, the increased morbidity and potentially decreased quality of life associated with radical surgery when compared with less invasive treatments.

ETRO logo

Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer

22.12.2021

Patients who received ACE2-lowering antineoplastic compounds, including mTOR/PI3K inhibitors and antimetabolites exhibited statistically significantly lower rates of SARS-CoV-2 infection compared with patients given other antineoplastics.

esso logo

A multidisciplinary approach for better Pancreatic Cancer care

22.12.2021

Pancreatic cancer is the fifth leading cause of cancer death in Europe. As cases are almost always diagnosed at an advanced stage, and with few treatment options available, the resulting 5-year survival rates are among the lowest (<5%) of any cancer.

esmo logo

Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular Lymphoma

21.12.2021

The ELARA investigators are now reporting the findings from the primary, prespecified interim analysis of their study of tisagenlecleucel in adults with relapsed/refractory follicular lymphoma after two or more treatment lines or who relapsed after autologous stem cell transplant.

esmo logo

EMA Recommends Extension of Indications for Lorlatinib

20.12.2021

EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product lorlatinib.bNew indication concerns the treatment of adult patients with ALK positive advanced NSCLC previously not treated with an ALK inhibitor.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the Treatment of Urothelial

17.12.2021

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product enfortumab vedotin, intended for the treatment of adult patients with urothelial cancer. An antibody drug conjugate induces cytotoxicity in cancer cells by binding to the nectin-4.

AACR logo

The Inaugural WHO Classification of Childhood Tumors Will Provide a Unified, Updated Resource for the Diagnosis of Pediatric Cancers

17.12.2021

The first classification of pediatric cancers soon to be published by the International Agency for Research on Cancer (IARC) as part of the new World Health Organization (WHO) Classification of Tumors series was summarized in a review article published in Cancer Discovery, a journal of the American Association for Cancer Research.

logo Narodowego Instytutu Onkologii oraz National Comprehensive Cancer Network

Powstała pierwsza polska edycja wytycznych NCCN dotycząca leczenia raka szyjki macicy

17.12.2021

W ramach międzynarodowej współpracy pomiędzy National Comprehensive Cancer Network a Narodowym Instytutem Onkologii opublikowano pierwszą polską edycję wytycznych NCCN dotyczących leczenia nowotworów. Opracowane w wyniku współpracy ekspertów wytyczne zostały oparte na dowodach naukowych i konsensusie ekspertów. Zawierają najnowsze zalecenia dotyczące leczenia nowotworów raka szyjki macicy.

European Cancer Organisation logo

European Cancer Summit 2021 Report: From Plans to Action

16.12.2021

2021 has exposed the weaknesses and lack of resilience of European healthcare systems with major consequences for cancer care and cancer patients, regrettably not too different from 2020. More than ever, this past year has stressed the need for crucial attention not only to restore cancer services but to build back better and be prepared to face upcoming challenges.

asco logo

Weighing Quality of Life Versus Survival for Patients With Advanced Prostate Cancer

16.12.2021

Over the past 5 years, clinical trials have demonstrated a clear benefit in overall survival with the intensification of upfront systemic therapy in the first-line treatment of metastatic and high-risk localized or node-positive prostate cancer.

Journal of Clinical Oncology

ASCO Guideline Update: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

16.12.2021

Purpose: to increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.

esmo logo

FDA Approves Pafolacianine for Identifying Malignant Ovarian Cancer Lesions

16.12.2021

FDA approved pafolacianine, an optical imaging agent, for adult patients with ovarian cancer as an adjunct for interoperative identification of malignant lesions. Pafolacianine is a fluorescent drug that targets folate receptor which may be overexpressed in ovarian cancer.

esmo logo

A Remarkable Group of Patients with Haematological Disorders with No or Low Immune Response After Second COVID-19 Vaccine Dose

15.12.2021

A remarkable group of patients were measured with no or low immune response after second COVID-19 vaccine dose, especially those with lymphoid neoplasms. Of those who tested negative for vaccine-related antibodies, most were on active therapy. The study team underlined that further explorations are needed with focus on potential risk of COVID-19 infections despite full vaccination.

European Cancer Organisation logo

Making Hope Reality: Action on Treatment and Care for Metastatic Cancer Patients

15.12.2021

The European Cancer Organisation has published a Report: “Making Hope Reality: Action on Treatment and Care for Metastatic Cancer Patients”. The report provides a detailed account of the presentations and contributions shared during a special Community 365 Roundtable Meeting on Metastatic Cancer held in October 2021.

asco logo

Exploring Future Directions for the Treatment of Neuroendocrine Neoplasms

15.12.2021

Several ongoing studies are researching the best combination strategies to improve response rates in neuroendocrine tumors with 177Lu-dotatate. Other promising treatment avenues for NETs include novel α-particle–emitting radiopharmaceuticals, as well as multireceptor tyrosine kinase inhibitors, both single agent and in combination with immune checkpoint inhibitors.

asco logo

New ASCO-SNO Guideline Addresses Treatment Recommendations Tailored to Glioma Subtypes

15.12.2021

Reflecting recent significant classification changes and new data on the use of biomarkers to inform treatment for central nervous system tumors, a new guideline offers oncologists up-to-date recommendations for managing gliomas in adult neuro-oncology patients.

ECO logo

Time to Charge Up Pancreatic Cancer Care Across Europe!

14.12.2021

The European Cancer Organisation, in strong alliance with a collaboration of 22 healthcare professional and patient organisations, is today marking the publication the "Essential Requirements for Quality Cancer Care: Pancreatic Cancer”. This new consensus charter for improved care and standards for a too-long neglected tumour type.

esmo logo

Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively Treated Solid Malignancies

14.12.2021

Results of the Vax-On study of mRNA-BNT162b2 immunogenicity in patients with actively treated solid malignancies suggest that proximity to cancer treatment does not affect seroconversion response, which remains adequate even 5 months after the second COVID-19 vaccine dose. Updated results of the Vax-On study favour the third vaccine dose for actively treated patients with cancer.

ESTRO logo

Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status

13.12.2021

This phase III randomised clinical trial found that hypofractionated IGRT (60 Gy in 15 fractions) was not superior to CFRT (60 Gy in 30 fractions) for patients with stage II/III NSCLC ineligible for concurrent chemoradiotherapy.

esmo logo

Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients with Stage I Low-Risk Breast Cancer, but Fewer Breast Cancer Events

13.12.2021

With 8 years median follow-up, a subgroup of patients included in the MINDACT study with stage I oestrogen receptor (ER)-positive, HER2-negative, low-risk breast cancer who received no adjuvant systemic therapy had a good 8-year distant metastasis-free interval rate, although a slightly better outcome and lower rates of locoregional recurrence and contralateral breast cancer were observed in patients who received endocrine therapy.

esmo logo

FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications

10.12.2021

FDA approved rituximab in combination with chemotherapy for paediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukaemia (B-AL).

baner XXVIII Konferencji Naukowo-Szkoleniowej Polskiego Towarzystwa Chirurgii Onkologicznej

XXVIII Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Chirurgii Onkologicznej

10.12.2021

Decyzją Zarządu Polskiego Towarzystwa Chirurgii Onkologicznej kolejny, XXVIII Zjazd PTChO w formie konferencji naukowo-szkoleniowej odbędzie się w dniach od 26 do 28 maja 2022 roku w Gdańsku. Jako przewodniczący Komitetu Organizacyjnego powołani zostali przez Zarząd profesorowie: Tomasz Jastrzębski i Zoran Stojcev.

Journal of Clinical Oncology

ASCO Guideline Update: Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative

10.12.2021

This guideline updates recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (MBC) that is either endocrine-pretreated or hormone receptor (HR)–negative.

Journal of Clinical Oncology

ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

10.12.2021

Purpose to update recommendations of the ASCO systemic therapy for hormone receptor (HR)-positive metastatic breast cancer (MBC) guideline. An Expert Panel conducted a systematic review to identify new, potentially practice-changing data.

Journal of Clinical Oncology

ASCO Guideline: Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy

10.12.2021

The multidisciplinary team issued recommendations to aid in the recognition, workup, evaluation, and management of the most common CAR T-cell–related toxicities, including cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, B-cell aplasia, cytopenias, and infections.

asco logo

ASCO Updates Guidance on Use of Abemaciclib and Endocrine Therapy in Patients With High-Risk Early Breast Cancer

09.12.2021

A rapid update to the ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for early breast cancer provides guidance on the use of the oral CDK4/6 inhibitor abemaciclib with endocrine therapy (ET) in patients with high-risk early breast cancer.

esmo logo

Two Years of Adjuvant Palbociclib Added to Endocrine Therapy Does Not Improve Outcomes in Early Breast Cancer

09.12.2021

The results of the final protocol-defined analysis of the PALLAS study conducted in patients with early hormone receptor-positive, HER2-negative breast cancer.

asco logo

Final PALLAS Analysis of Palbociclib for Breast Cancer Misses Primary Endpoint

09.12.2021

Addition of adjuvant palbociclib to standard endocrine therapy does not improve outcomes in patients with early HR-positive breast cancer.

asco logo

CAR T-Cell Treatment for Adults With Relapsed/Refractory B-Cell ALL: Understanding ZUMA-3 Data and Next Steps

08.12.2021

Based on the ZUMA-3 data, the FDA recently approved brexucabtagene autoleucel for adult patients with R/R B-ALL. CAR T cells should be incorporated in earlier lines of therapy and, importantly, in MRD-positive/low-tumor-burden disease states.

esmo logo

FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma

07.12.2021

FDA approved pembrolizumab for the adjuvant treatment of adult and paediatric patients with stage IIB or IIC melanoma following complete resection. Efficacy was evaluated in KEYNOTE-716.

esmo logo

Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in Low PD-L1–Expressing Gastric, Gastro-oesophageal Junction, or Oesophageal Adenocarcinoma

06.12.2021

Although current recommendations suggest that immune checkpoint inhibitors may be used for all patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma in the first-line setting, the analyses of previously unpublished data from pivotal phase III randomised studies fail to demonstrate a survival advantage when adding ICIs to conventional chemotherapy in patients with low PD-L1–expressing tumours.

ESTRO logo

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)

06.12.2021

In this randomised clinical trial, neither arm demonstrated evidence of superior safety, efficacy, or symptom burden; however, single-fraction SABR is more efficient to deliver. Therefore, single-fraction SABR, as assessed by the most acceptable outcome profile from all end points, could be chosen to escalate to future studies.

esmo logo

p53 Mutations May Differentially Affect Survival of Patients with mCRC Based on Anatomic Location

03.12.2021

When classified into gain-of-function and non–gain-of-function, p53 mutations could stratify the prognosis of right-sided versus left-sided metastatic colorectal cancer.

esmo logo

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with carcinoma of unknown primary

01.12.2021

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of patients with carcinoma of unknown primary.

AACR logo

Sequencing of Bone Marrow DNA May Predict Leukemia Relapse After CAR-T Therapy With Sufficient Time to Intervene

01.12.2021

Next-generation sequencing for minimal residual disease was highly sensitive and more accurate than flow cytometry and monitoring of B-cell aplasia. according to a study published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Annals of Oncology logo

Bladder Cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

30.11.2021

This ESMO Clinical Practice Guideline provides key recommendations for diagnosis, staging and management of bladder cancer. Recommendations for personalised medicine are also included.

Annals of Oncology logo

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

30.11.2021

This ESMO Clinical Practice Guideline provides key recommendations for managing malignant pleural mesothelioma. The optimal diagnostic methods, pathological evaluation and staging are described.

PTO logo

Stanowisko Polskiego Towarzystwa Onkologicznego w sprawie projektu Ustawy o Krajowej Sieci Onkologicznej

30.11.2021

Jak wskazuje NIK, skuteczność leczenia onkologicznego w Polsce jest gorsza niż w większości pozostałych krajów Unii Europejskiej, a według dostępnych prognoz istnieje ryzyko, że stan ten będzie się pogarszał. Tym samym potrzebne są istotne zmiany o charakterze systemowym, które przekładać się będą na poprawę wyników osiąganych w diagnozowaniu i leczeniu nowotworów.

NICE logo

Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund

30.11.2021

Osimertinib is recommended for people with early-stage (1b to 3a) non-small-cell lung cancer (NSCLC) who have had surgery to remove their tumour and who have epidermal growth factor receptor (EGFR) gene mutations.

esmo logo

Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond Delayed CINV

30.11.2021

The results from a head-to-head comparison of two different neurokinin-1 receptor antagonists for the prevention of chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

esmo logo

Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced Melanoma

29.11.2021

The 6.5-year data in the pivotal CheckMate 067 study show durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy.

ESTRO logo

Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose

29.11.2021

The biological effect of radiotherapy, as quantified by GARD, is significantly associated with time to first recurrence and overall survival for patients with cancer treated with radiation. It is predictive of radiotherapy benefit, and physical dose of radiation is not.

JCO logo

Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma

29.11.2021

Support for the role of neoadjuvant therapy in the management of nonmetastatic pancreatic adenocarcinoma is growing. With the high risk of rapid dissemination of disease, neoadjuvant therapy allows for the immediate delivery of systemic therapy to address micrometastatic disease present in most patients with localized pancreatic cancer at the time of diagnosis.

PTO logo

Konferencja „Warsaw Summit of European Cancer Strategies”

26.11.2021

Narodowy Instytut Onkologii zaprasza do udziału w konferencji „Warsaw Summit of European Cancer Strategies”, która odbędzie się 9 grudnia 2021r. w formie hybrydowej (w NIO w Warszawie oraz na platformie Zoom). Szczyt poświęcony będzie różnorodnym tematom związanym z walką z rakiem, europejskim sieciom onkologicznym i wdrażaniu strategii onkologicznych w Europie Środkowo-Wschodniej.

esmo logo

FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour

26.11.2021

Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour.

PTChO logo

PTChO zaprasza na webinar dotyczący chirurgii małoinwazyjnej

25.11.2021

Będzie to czwarty w tym roku webinar organizowany przez sekcję młodych chirurgów onkologicznych. Tematyką webinaru będzie chirurgia małoinwazyjna. Czy można się nauczyć chirurgii małoinwazyjnej nie mając od kogo na oddziale? Czy trzeba być dobrym laparoskopistą aby dobrze operować robotem?

JCO logo

Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?

25.11.2021

In 2004, the MOSAIC trial demonstrated that fluoropyrimidine-oxaliplatin doublets further improved OS for stage III disease6; this led to widespread use of perioperative or adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for resectable colorectal cancer liver metastases.

esmo logo

Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer

24.11.2021

In a phase III, randomised DAWNA-1 study, the combination of dalpiciclib, a new cyclin-dependent kinase (CDK) 4 and 6 inhibitor, with fulvestrant improved progression-free survival with manageable safety in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer who progressed or relapsed on endocrine therapy.

esmo logo

ctDNA-Guided Therapy with Pertuzumab plus Trastuzumab for HER2-Amplified mCRC

23.11.2021

Results from the first prospective study showing that patients with HER2-amplified metastatic colorectal cancer identified by ctDNA genotyping benefit from dual-HER2 blockade similarly to patients identified by conventional tissue analysis,

EORTC logo

Results from monotherapy group in UPSTREAM demonstrate trial’s feasibility in head and neck squamous cell carcinoma

23.11.2021

The EORTC UPSTREAM trial set out to investigate the effect of targeting treatment to the specific gene alteration (biomarker) found in an individual patient’s tumour. Patients for whom no pre-specified biomarkers are identified in their tumour are treated by immunotherapy.

ESSO logo

Europe’s Beating Cancer Plan Implementation Roadmap published

23.11.2021

The implementation roadmap for the Europe's Beating Cancer Plan has now been published by the European Commission. It highlights the necessary steps to be taken in concrete actions towards a strong European Health Union.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib

22.11.2021

It is intended for the treatment of patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy.

ESTRO logo

Randomised Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer

22.11.2021

In definitive chemoradiation for esophageal cancer, radiation dose escalation up to 61.6 Gy to the primary tumour did not result in a significant increase in local control over 50.4 Gy. The absence of a dose effect was observed in both adenocarcinoma and squamous cell carcinoma.

ASTRO logo

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline

19.11.2021

This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC).

esmo logo

FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

19.11.2021

FDA approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

asco logo

Promising CAR T-Cell Therapies Emerge for Multiple Myeloma

18.11.2021

CAR T-cell therapy has recently entered standard-of-care practice for multiple myeloma with the U.S. Food and Drug Administration's approval of idecabtagene vicleucel and imminent review of ciltacabtagene autoleucel.

asco logo

Study Identifies Determinants of Response to SARS-CoV-2 Vaccines Among Patients With Solid-Organ and Hematologic Malignancies

18.11.2021

A recent study from Journal of Clinical Oncology found all 3 SARS-CoV-2 vaccines authorized for use in the United States to be well-tolerated in a large cohort of patients with solid-organ and hematologic malignancies.

NICE logo

Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer

17.11.2021

Nivolumab is recommended for adjuvant treatment of completely resected oesophageal or gastro‑oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy.

AACR logo

Fasting-mimicking Diet Is Safe, May Modulate Metabolism and Boost Antitumor Immunity in Cancer Patients

17.11.2021

A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood glucose and growth factor concentration, reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration in cancer patients receiving standard-of-care therapy.

asco logo

Exploring Controversies Surrounding First-Line Therapy for Metastatic Urothelial Cancer

17.11.2021

Results from two phase III studies, KEYNOTE-361 and IMvigor131, using combination chemotherapy and CPI therapy versus chemotherapy alone or CPI monotherapy showed no clear benefit with combination treatment.

asco logo

Early Onset Is a Negative Prognostic Factor in High-Risk Stage III CRC, Hinting to Aggressive Nature of the Disease

17.11.2021

A post hoc analysis of the database of the IDEA collaboration published in Journal of Clinical Oncology found young age to be negatively prognostic and associated with significantly higher relapse rate in patients with stage III early-onset colorectal cancer (EO-CRC), irrespective of greater treatment intensity and adherence.

asco logo

DREAMseq: Upfront Dual Immunotherapy More Efficacious Than Dual Targeted Therapy for BRAFV600-Mutant Metastatic Melanoma

15.11.2021

The randomized phase III ECOG-ACRIN EA6134 trial, also known as DREAMseq, demonstrates that for the 45% of patients with BRAFV600-mutant metastatic melanoma, starting with anti–PD-1/CTLA-4 immunotherapy confers better overall survival (OS) than starting with BRAF/MEK targeted therapy.

ESTRO logo

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer

15.11.2021

Six months of concomitant and adjuvant androgen suppression statistically significantly improves EFS and clinical disease-free survival in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance.

ECO logo

Catching All Cancers Earlier: A Critical Principle for New EU Recommendations

15.11.2021

In ‘Earlier is Better: Advancing Cancer Screening and Early Detection’ the European Cancer Organisation, working with its dedicated Network on Prevention, Early Detection and Screening, has set out a number of pressing needs to be encapsulated in the new formal advice on cancer screening.

AACR logo

Immunotherapy May Yield Longer Treatment-free Survival Than Targeted Therapy in Advanced Renal Cell Carcinoma

10.11.2021

Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab plus ipilimumab experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib, regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group.

asco logo

Immunotherapy in Gastroesophageal Cancer: Is It One Size Fits All or Only If the CPS Fits?

10.11.2021

Chemo-immunotherapy improves overall survival compared with chemotherapy alone and represents a new standard of care for all patients with untreated advanced esophageal squamous cell carcinoma and most patients with untreated advanced gastroesophageal adenocarcinomas.

asco logo

What Role Do Bispecific Antibodies Play in B-Cell Non-Hodgkin Lymphoma?

10.11.2021

Bispecific antibodies are molecules designed to target malignant cells and immune effector cells simultaneously, they act as a bridge between these two antigens and result in cell-mediated cytotoxicity.

asco logo

Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?

10.11.2021

Disease-free survival (DFS) is one of the most complicated endpoints in oncology. Unlike progression-free survival in the advanced cancer setting, which refers to time from treatment to disease progression (or death) in patients who already have measurable cancer in their bodies.

ESSO logo

ESSO Open letter "Time for Change"

09.11.2021

High-quality surgery remains the best chance to cure solid cancer when diagnosed early and is fundamental in preventing, diagnosing and staging cancer, treating metastatic disease, preserving quality of life and alleviating symptoms. However, many challenges remain to fully unlock its potential.

ESTRO logo

Randomised Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer

08.11.2021

Sparing the hippocampus during prophylactic cranial irradiation (PCI) better preserves cognitive function in patients with SCLC. No differences were observed with regard to brain failure, OS, and QoL compared with standard PCI.

esmo logo

EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices on the Planning and Conduct of Registry-Based Studies

08.11.2021

EMA published the guideline on registry-based studies. This guideline addresses the methodological, regulatory and operational aspects involved in using registry-based studies to support regulatory decision-making.

asco logo

Considering the High Unmet Need in Triple-Negative Breast Cancer

04.11.2021

Metastatic TNBC (mTNBC) is associated with poor prognosis. A recent analysis of France's Epidemiological Strategy and Medical Economics database showed that outcomes for mTNBC have not improved much over the last decade.

asco logo

Evaluating the Use of BTK Inhibitors in Combination With BCL-2 Inhibitors in Treatment-Naïve CLL

04.11.2021

In an effort to design a more effective, time-limited regimen, BTK inhibitors have now been combined with venetoclax, with or without obinutuzumab; these combination regimens capitalize on the potentially synergistic effects of BTK and BCL-2 inhibitors.

asco logo

ASCO Releases New Guidelines on the Management of Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and CAR T-Cell Therapy

03.11.2021

ASCO has released new recommendations for the management of adverse events related to two immunotherapy modalities with increasing application in cancer care—immune checkpoint inhibitors (ICIs) and CAR T-cell therapy.

esmo logo

FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia

03.11.2021

FDA granted accelerated approval to asciminib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and approved asciminib for adult patients with Ph+ CML in CP with the T315I mutation.

AACR logo

Risk of Age-related Diseases May Be Higher in Younger B-cell Non-Hodgkin Lymphoma Survivors Than in Their Older Counterparts

03.11.2021

Younger B-cell non-Hodgkin lymphoma (B-NHL) survivors had a higher relative risk of developing age-related diseases than older B-NHL survivors five years or more after cancer diagnosis, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

NICE logo

Selpercatinib for treating advanced thyroid cancer with RET alterations

03.11.2021

Selpercatinib is recommended for use within the Cancer Drugs Fund, as an option for treating: advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib, advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib.

esmo logo

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy

02.11.2021

Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk.

JCO logo

Risk of Late-Onset Breast Cancer in Genetically Predisposed Women

01.11.2021

This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab

29.10.2021

EMA adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product amivantamab intended for the treatment of advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

NICE logo

Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

28.10.2021

Apalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults. High risk is defined as a blood prostate-specific antigen (PSA) level that has doubled in 10 months or less on continuous ADT.

NICE logo

Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

28.10.2021

Apalutamide plus androgen deprivation therapy (ADT) is recommended as an option for treating hormone-sensitive metastatic prostate cancer in adults, only if docetaxel is not suitable.

asco logo

Patients With Early-Stage Breast Cancer Who Are Unrepresented in Clinical Trials Face Increased Mortality

28.10.2021

New data on women with early breast cancer, presented during the 2021 ASCO Quality Care Symposium, suggest patients who are not well-represented in clinical trials may face reduced odds of survival, calling into question the generalizability of clinical trial results to real-world patients.

esmo logo

Long-Term Outcomes in Patients with Metastatic Melanoma Treated with Anti-PD1 Therapy Based on PET Response

28.10.2021

FDG-PET has a predominant role in predicting long-term benefit over CT, especially in patients with no complete response. In those without CMR at 1-year, almost half will experience subsequent disease progression, such that a change in therapy could be implemented, whereas in CMR patients, FDG-PET may have a role in defining shorter treatment duration.

asco logo

nab-Sirolimus Induces Rapid and Durable Responses in Patients With Malignant Perivascular Epithelioid Cell Tumors

27.10.2021

A new study from Journal of Clinical Oncology reporting on the outcomes from the phase II AMPECT trial found that rapamycin inhibitor nab-sirolimus induces rapid and durable responses in patients with malignant perivascular epithelioid cell tumors (PEComas).

asco logo

Patient Selection, Risk Management, Critical to Treating Asymptomatic Brain Metastasis in Patients With Non–Small Cell Lung Cancer

27.10.2021

Up to a quarter of patients with advanced non–small cell lung cancer (NSCLC) that doesn't harbor a driver mutation can develop brain metastases (mets), and they contribute to neurocognitive symptoms and diminished quality of life.

esmo logo

Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated with Increased Risk of Invasive Lobular Carcinoma

27.10.2021

The largest study involving multigene panel testing of women with invasive lobular carcinoma describes the frequency of germline pathogenic variants in invasive lobular carcinoma and the differences in gene-specific frequencies between invasive lobular carcinoma and infiltrating ductal carcinoma.

ECO logo

Patients with Non-Small-Cell Lung Cancer with Brain Metastases: New Data on the Significant Challenges for which Physicians Feel Unequipped

27.10.2021

40 per cent of healthcare providers surveyed across the five countries in Europe and the United States feel less than well equipped to care for non-small-cell lung cancer (NSCLC) patients with brain metastases, according to a new survey carried out by Ipsos MORI in collaboration with the European Cancer Organisation.

NICE logo

Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable

27.10.2021

Atezolizumab is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic urothelial cancer in adults whose tumours express PD-L1 at a level of 5% or more and when cisplatin-containing chemotherapy is unsuitable.

NICE logo

NICE draft guidance does not recommend tucatinib for advanced breast cancer

26.10.2021

NICE has published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.

ASTRO logo

Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery

26.10.2021

Using fewer - but higher - doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.

esmo logo

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

26.10.2021

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were published on 22 October 2021 in the Journal of Clinical Oncology.

NCCN logo

Wytyczne NCCN w zakresie praktyki klinicznej w onkologii - Rak jajnika w tym rak jajowodu i pierwotny rak otrzewnej

25.10.2021

Opublikowana została polska wersja językowa wytycznych National Comprehensive Cancer Network (NCCN) w zakresie praktyki klinicznej w onkologi dotycząca raka jajnika wraz z rakiem jajowodu i pierwotnym rakiem otrzewnej. Polska edycja powstała w ramach współpracy pomiędzy NCCN, USA a Narodowym Instytutem Onkologii im. Marii Skłodowskiej-Curie (NIO-PIB).

ASTRO logo

Genetic biomarker test predicts recurrence and survival outcomes for men with high-risk prostate cancer

25.10.2021

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy. The study indicates that physicians potentially can use genetic test scores to personalize treatment for men with the most aggressive form of prostate cancer.

ESTRO logo

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node

25.10.2021

Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

25.10.2021

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the first-in-class medicinal product sacituzumab govitecan, intended for the treatment of unresectable or metastatic triple negative breast cancer (TNBC).

ASTRO logo

High-dose radiation thwarts tumor growth in patients with advanced lung cancer

24.10.2021

High-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases, according to a new study.

esmo logo

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

22.10.2021

FDA approved atezolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥1% of tumour cells, as determined by an FDA-approved test.

asco logo

Bulky Early-Stage Hodgkin Lymphoma: Using PET Scans as a Biomarker to Direct Therapy

21.10.2021

Clinical trial reported at the 2021 ASCO Annual Meeting confirmed that the use of interim PET/CT scans is highly valuable as a biomarker of disease and can successfully be used to improve patient outcomes.

esmo logo

Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for MSI-H/dMMR mCRC

20.10.2021

Durable and deep tumour responses were observed in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) treated with first-line nivolumab plus low-dose ipilimumab, regardless of baseline demographic and tumour characteristics, including BRAF or KRAS mutation status.

NICE logo

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy

20.10.2021

Nivolumab is recommended as an option for treating recurrent or metastatic squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum based chemotherapy, only if the disease has progressed within 6 months of having chemotherapy

NICE logo

Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer

20.10.2021

Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy is recommended, within its marketing authorisation, as an option for untreated locally advanced unresectable or metastatic carcinoma of the oesophagus or HER2‑negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 10 or more.

Annals of Oncology logo

ESMO Clinical Practice Guideline – Metastatic Breast Cancer

19.10.2021

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Provides key recommendations and algorithms for managing metastatic breast cancer. Covers diagnosis, staging, risk assessment, treatment, disease monitoring, palliative care and the patient perspective.

esmo logo

Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative, Node-Positive, High-Risk, Early Breast Cancer

19.10.2021

Invasive disease-free survival benefit deepened and distant relapse-free survival benefit was maintained in patients with hormone receptors (HR)-positive, HER2-negative, node-positive, high risk early breast cancer treated with adjuvant CDK4/6 inhibitor, abemaciclib and endocrine therapy.

esmo logo

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening

18.10.2021

MRI with targeted and standard biopsy in men with MRI results suggestive of prostate cancer was noninferior to standard biopsy for detecting clinically significant prostate cancer in a population-based screening-by-invitation trial and resulted in less detection of clinically insignificant cancer.

ESTRO logo

Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients With Lymphoid Malignancies

18.10.2021

In heavily pretreated patients with lymphoid malignancies, zilovertamab vedotin demonstrated no unexpected side effects and showed evidence of antitumour activity in a phase I, first-in-human, dose-escalation study.

baner webinaru „Prevention and Treatment of Peritoneal Metastases: Combining Complete Cytoreductive Surgery with HIPEC”

Webinar „Prevention and Treatment of Peritoneal Metastases: Combining Complete Cytoreductive Surgery with HIPEC”

18.10.2021

7 listopada 2021 w niedzielę o godzinie 20.00 czasu indyjskiego (16:30 czasu polskiego) odbędzie się webinar "Prevention and Treatment of Peritoneal Metastases: Combining Complete Cytoreductive Surgery with HIPEC". Będzie to niesamowita okazja by posłuchać profesora Paula Sugarbakera z USA, ojca chirurgii HIPEC.

esmo logo

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

15.10.2021

FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumours express PD-L1 combined positive score (CPS) ≥1

PTChO logo

Warsztaty diagnostyki biopsyjnej i leczenia chirurgicznego z rekonstrukcją gruczołu piersiowego

15.10.2021

PTCHO objęło patronatem merytorycznym warsztaty dotyczące diagnostyki biopsyjnej i leczenia chirurgicznego z rekonstrukcją gruczołu piersiowego, które odbędą się na utrwalonych preparatach anatomicznych. Warsztaty są skierowano głównie do osób w trakcie specjalizacji.

ECO logo

The European Cancer Organisation Publishes a Position Paper on Self-Sampling and HPV Screening in Europe

14.10.2021

The Europe’s Beating Cancer Plan sets out recommendations for cervical cancer elimination across the EU, including an ambitious goal to offer screening to 90% of the eligible population by 2025. The ECO today publishes a new Position Paper “Self-Sampling and HPV Screening in Europe” with recommendations that will help member states achieve this.

esmo logo

EMA Recommends Extension of Indications for Pembrolizumab

14.10.2021

EMA adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product pembrolizumab. New indication concerns the treatment of PD-L1 positive locally recurrent unresectable or metastatic TNBC.

AACR logo

AACR Cancer Progress Report Highlights How Discovery Science is Driving Clinical Breakthroughs

13.10.2021

American Association for Cancer Research (AACR) released the 11th edition of its annual Cancer Progress Report, which underscores how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), continues to drive progress for patients with cancer.

esmo logo

A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity Against SARS-CoV-2 in Patients with Solid Tumours

12.10.2021

Researchers reported the serological and cellular immune responses after two-dose BNT162b2 vaccination of patients with solid tumours on active cytotoxic chemotherapy compared to healthy controls and the outcomes of a phase I study of a third vaccine dose subsequently initiated in the cancer cohort.

esmo logo

Merging the Histologic and Molecular Data Into an Integrated Score Significantly Improves Precision in Stratification of Meningiomas

11.10.2021

Retrospectively and prospectively validated data from a multicentre retrospective analysis allowed to the German Consortium on Aggressive Meningiomas researchers to devise and validate an integrated score that leverages the advantages of WHO grading, specific copy-number variations (CNVs), and methylation-based classifications.

ASTRO logo

ASTRO przedstawia najważniejsze badania, które zostaną omówione na tegorocznym kongresie

11.10.2021

Amerykańskie Towarzystwo Radioterapii Onkologicznej (ASTRO) przedstawiło zestawienie najważniejszych badań, których wyniki zostaną omówione podczas dorocznego Kongresu ASTRO, który odbędzie się 24 -27 października w Chicago w formie tradycyjnej oraz online.

esmo logo

Nowa publikacja o nowotworach skóry - „Melanoma and other skin cancers”

08.10.2021

Prof. Iwona Ługowska, Ruth Plummer i Paulo A. Ascierto napisali „Melanoma and other skin cancers” – dwuczęściowy informator – przewodnik poświęcony czerniakowi i innym rodzajom raka skóry. Powodem tej publikacji są nowe możliwości leczenia pacjentów. Autorzy zebrali dostępną sobie wiedzę i dzielą się nią ze środowiskiem medycznym w nowej publikacji.

esmo logo

FDA Recognises OncoKB Database of Molecular Tumour Marker Information

08.10.2021

FDA granted recognition to a partial listing of the Memorial Sloan Kettering Cancer Center’s Oncology Knowledge Base (OncoKB) as the first tumour mutation database to be included in the Public Human Genetic Variant Database.

AACR logo

A Peptide-drug Conjugate that Targets the Acidic Environment of Cancer Cells May Improve the Efficacy of Immunotherapy

07.10.2021

A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint inhibitors in preclinical cancer models, according to results presented at the AACR-NCI-EORTC Virtual International Conference.

AACR logo

Inhibition of the Aurora Kinase A Protein May Help Overcome Lung Cancer Resistance to KRAS Inhibition

07.10.2021

In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired resistance to KRAS inhibition.

AACR logo

Adding ErbB Tyrosine Kinase Inhibitor to KRAS Inhibitor May Help Circumvent Lung Cancer Resistance to Prior Therapies

07.10.2021

Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinaseinhibitor, was feasible in treating non-small cell lung cancer (NSCLC) patients with mutated KRAS whose disease had progressed on prior therapies, including KRAS inhibitors alone.

AACR logo

DNA Alkylation Drug May Improve Outcomes for Adolescents and Young Adults With Central Nervous System Tumors

07.10.2021

In a phase II clinical trial, the drug 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) improved survival for some adolescent and young adult (AYA) patients with cancers involving the central nervous system, according to results presented at the AACR-NCI-EORTC Virtual International Conference.

esmo logo

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia

07.10.2021

FDA approved brexucabtagene autoleucel for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Efficacy was evaluated in ZUMA-3 study that evaluated brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in adults with relapsed or refractory B-cell precursor ALL.

AACR logo

Chronic Stress May Impact Treatment Completion and Survival Outcomes in Patients with Breast Cancer

06.10.2021

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer.

esmo logo

Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does Not Improve Efficacy in Resected NSCLC

06.10.2021

ITACA study was open-label, randomised, investigator-initiated study to evaluate the predictive utility of ERCC1 and TS mRNA expression levels in completely resected stage II-IIIA non-small cell lung cancer. The results indicate that adjuvant chemotherapy customisation based on ERCC1 and TS mRNA levels did not improve efficacy.

asco logo

Promising FOCUS4-C Findings Warrant Further Study of WEE1 Blockade in TP53- and RAS-Mutant Metastatic Colorectal Cancer

06.10.2021

Adavosertib, an investigational small-molecule inhibitor of WEE1, demonstrated encouraging efficacy and favorable safety in the phase II FOCUS4-C trial conducted in 69 patients with metastatic colorectal cancer (CRC) featuring TP53 and RAS mutations.

Agencja Badań Medycznych logo

ABM ogłasza konkurs dla Onkologicznych Centrów Wsparcia Badań Klinicznych

05.10.2021

W ramach konkursu Agencja Badań Medycznych dofinansuje projekty przewidujące utworzenie i rozwój Onkologicznych Centrów Wsparcia Badań Klinicznych (OnkoCWBK). Inicjatywa ma na celu zwiększenie liczby zarówno badań klinicznych w obszarze onkologii, zwiększenie liczby uczestników w Polsce, a także wykorzystanie potencjału sektora badań klinicznych komercyjnych i niekomercyjnych.

esmo logo

EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment of Advanced GIST

05.10.2021

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ripretinib, intended for the treatment of advanced gastrointestinal stromal tumour (GIST) in patients who have received prior treatment with three or more kinase inhibitors.

esmo logo

Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe in AR-Expressing, Castration-Resistant Salivary Gland Carcinoma

04.10.2021

The primary aim of the phase II study was reached, demonstrating for the first time that abiraterone acetate combined with prednisone and luteinizing hormone-releasing hormone (LHRH) analogue is active in castration-resistant, androgen receptor (AR)-positive salivary gland carcinoma.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Nivolumab

01.10.2021

New indication concerns the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, GEJ or oesophageal adenocarcinoma.

esmo logo

Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological Response to COVID-19 Vaccination

01.10.2021

Findings from the largest study to measure anti-SARS-CoV-2 antibody levels after vaccination in patients with haematological and solid malignant tumours.

Journal of Clinical Oncology logo

Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update

01.10.2021

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual.

asco logo

FOCUS4-N Supports a Treatment Break as a Sound Alternative to Maintenance Therapy in Metastatic Colorectal Cancer

30.09.2021

The meta-analysis, like FOCUS4-N, showed that “although maintenance therapies can extend the time to progression, they have no impact on OS. This includes the standard range of therapies, capecitabine and bevacizumab being the cardinal ones.

esmo logo

FDA Approves Cabozantinib for Differentiated Thyroid Cancer

30.09.2021

FDA approved cabozantinib for adult and paediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are ineligible or refractory to radioactive iodine.

NICE logo

People with advanced or metastatic urothelial cancer to get life-extending treatment

30.09.2021

Atezolizumab has been recommended by NICE for people whose tumour expresses PD-L1 at a level of 5% of more and when platinum-containing chemotherapy is unsuitable. The recommendation comes after additional clinical evidence which showed that people who have atezolizumab are likely to live up to 8 months longer than those who have platinum-containing chemotherapy.

asco logo

PROs Predicted Responses, Survival at 1-Month in GI Cancers

29.09.2021

Changes in patient-reported outcomes (PROs) seen after just 1 month predicted for treatment response and survival outcomes in patients with advanced gastrointestinal cancers, according to data presented during the 2021 ASCO Quality Care Symposium.

esmo logo

Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20 Mutated NSCLC

29.09.2021

In a phase II study conducted by the MD Anderson Cancer Center researchers, poziotinib resulted in a 27% confirmed partial response (PR) rate and a median progression-free survival (PFS) of 5 months in patients with advanced HER2 exon 20 mutated non-small cell lung cancer (NSCLC).

esmo logo

eUpdate – Renal Cell Carcinoma Treatment Recommendations

28.09.2021

This article focuses on the recent immunotherapy updates to the treatment of renal cell carcinoma (RCC) as given in the RCC: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib

28.09.2021

EMA adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product pralsetinib, intended for the treatment of patients with rearranged during transfection (RET) fusion positive non-small cell lung cancer (NSCLC).

Kongres ESMO 2021 – baner

Rybocyklib z najdłuższą medianą przeżycia całkowitego kiedykolwiek zaobserwowaną w zaawansowanym HR+/HER2-ujemnym raku piersi

28.09.2021

Rybocyklib w skojarzeniu z letrozolem, u kobiet w wieku pomenopauzalnym z zaawansowanym rakiem piersi typu HR+/HER2-, pozwolił osiągnąć medianę przeżycia całkowitego wynoszącą ponad 5 lat (63,9 miesiąca), korzyść w zakresie przeżycia wyniosła ponad 12 miesiący.

ESTRO logo

Palliative radiotherapy after oesophageal cancer stenting (ROCS)

27.09.2021

Patients with advanced oesophageal cancer having SEMS insertion for the primary management of their dysphagia did not gain additional benefit from concurrent palliative radiotherapy and it should not be routinely offered.

esmo logo

Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated Patients with Metastatic Uveal Melanoma

27.09.2021

In the randomised, phase III study, treatment with tebentafusp, a soluble T-cell receptor and CD3-directed bispecific fusion protein, was associated with longer overall survival (OS) than the investigator’s choice of therapy in HLA-A*02:01– positive patients with metastatic uveal melanoma.

esmo logo

Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole COVID-19 Vaccination Schedule

24.09.2021

In a large population of patients with solid tumours undergoing active anticancer treatment, the researchers confirmed a favourable safety profile of mRNA-BNT162b2 vaccine, which may reassure on maintaining active anticancer treatment throughout the whole vaccination schedule.

NCCN logo

Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?

23.09.2021

New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.

esmo logo

FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

23.09.2021

FDA granted accelerated approval to tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

esmo logo

Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in RAS Wild-Type mCRC

22.09.2021

The findings from the first randomised study that evaluated the addition of an epidermal growth factor receptor (EGFR) antibody to fluorouracil/folinic acid maintenance therapy in patients with RAS wild-type metastatic colorectal cancer show that panitumumab adds efficacy to fluorouracil/folinic acid as maintenance therapy in terms of progression-free survival.

asco logo

Radioembolization Delays Disease Progression in Patients With Unresectable Colorectal Liver Metastases

22.09.2021

Long-awaited findings from the EPOCH trial demonstrate that a locoregional therapy can confer a clinically meaningful benefit in patients with systemic disease. This randomized phase III trial conducted over 8 years in individuals with unresectable colorectal liver metastases.

asco logo

Multifocal Disease in Soft Tissue Sarcomas: A ‘Black Sheep’

22.09.2021

In soft tissue sarcomas (STS), several aspects about multifocal disease (MFD) —the presence of two or more discontiguous tumors within one body location —are still unclear. Liposarcoma is the most common histologic subtype to have MFD, but it can also occur in angiosarcoma.

esmo logo

A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and Acceptable Tolerability in Advanced RCC

21.09.2021

In the COSMIC-021 study, cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes.

esmo logo

People with Intellectual Disability at Increased Risk of Cancer

21.09.2021

People with intellectual disability are at an increased risk of any cancer, as well as several specific cancer types. The findings from a population-based cohort study of Swedish children born to mothers from the Nordic countries suggest a need for extended surveillance and early intervention in cancer among people with intellectual disability.

esmo logo

Clinical Practice Guidelines – Gastrointestinal Stromal Tumours

21.09.2021

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guideline for diagnosis, treatment and follow-up. This Clinical Practice Guideline provides key recommendations on the management of gastrointestinal stromal tumours. Recommendations have been agreed following a consensus meeting of representatives from ESMO, EURACAN and GENTURIS.

ESTRO logo

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer

20.09.2021

Intensification of chemotherapy using FOLFIRINOX before preoperative chemoradiotherapy significantly improved outcomes compared with preoperative chemoradiotherapy in patients with cT3 or cT4 M0 rectal cancer. The significantly improved disease-free survival in the neoadjuvant chemotherapy group and the decreased neurotoxicity indicates that the perioperative approach is more efficient and better tolerated than adjuvant chemotherapy.

esmo logo

Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

20.09.2021

According to results of the KEYNOTE-122, multicentre, open-label, randomised phase III study that evaluated the efficacy and safety of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma, pembrolizumab did not prolong overall survival (OS) over chemotherapy in that population.

esmo logo

Automated Detection of Microsatellite Status in Early Colon Cancer by Infrared Imaging Combined with Artificial Intelligence

20.09.2021

The researchers of PRODI used tissue sections from the prospective multicentre AIO ColoPredictPlus 2.0 registry study to verify the novel label-free infrared (IR) imaging combined with artificial intelligence (AI) for tumour detection and classification of microsatellite status. They reported that AI integrated IR imaging can automatically classify unstained tumour sections precisely in less than 30 min.

esmo logo

Copanlisib Combined with Rituximab Shows Superior Efficacy over Placebo and Rituximab in Relapsed Marginal Zone Lymphoma

20.09.2021

A subset analysis of the randomised, double-blind, placebo-controlled phase III CHRONOS-3 study that focused on patients with relapsed marginal zone lymphoma, showed superior efficacy of treatment with a PI3K inhibitor, copanlisib plus rituximab compared to placebo plus rituximab.

esmo logo

FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma

20.09.2021

FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

EORTC logo

New results from immunotherapy trials from the EORTC gynaecological and lung cancer groups presented at ESMO 2021

20.09.2021

Late-breaking results from two Phase 2 EORTC trials of immunotherapy were presented at the 2021 ESMO congress on Friday 17 September. Immunotherapy drugs are relatively new additions to cancer treatment, and work by stimulating the immune system so that it can find and attack cancer cells.

esmo logo

Organ-Sparing Potentials from the Neoadjuvant Pembrolizumab Treatment in Patients with dMMR/MSI-H Solid Tumours

19.09.2021

In a phase II open-label study performed among patients with localised, unresectable or high risk resectable, microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumours, treatment with neoadjuvant pembrolizumab was safe and resulted in high rates of radiographic and endoscopic responses.

esmo logo

Deep Learning Model Applied to Digital Pathology Slides Could Predict the Risk of Relapse in Invasive Breast Cancer

19.09.2021

To better identify patients with early breast cancer who are at risk of relapse, the researchers from the startup Owkin and Gustave Roussy conceived a diagnostic tool that applies deep learning to digital pathology slides and clinical data. They showed that their model could predict the risk of relapse in patients with oestrogen receptor (ER)-positive, HER2-negative early breast cancer.

esmo logo

Safety and Antitumour Activity of a First-in-Class, Oral, Selective CDK7 Inhibitor

18.09.2021

Tolerability, pharmacokinetics and efficacy of samuraciclib were assessed in a first-in-human, modular study. Treatment with this first-in-class, oral, selective inhibitor of CDK7 demonstrated an acceptable safety profile and evidence of antitumour activity in patients with advanced solid tumours.

esmo logo

Trastuzumab Deruxtecan Demonstrates Robust and Durable Activity in Previously Treated Metastatic NSCLC with HER2 mutations

18.09.2021

The DESTINY-Lung01 study assessed the efficacy and safety of HER2 antibody-drug conjugate trastuzumab deruxtecan in patients with metastatic non-small cell lung cancer (NSCLC) with HER2 mutations. Trastuzumab deruxtecan demonstrated robust and durable activity in this population, with a manageable safety profile.

PTOK logo

Szkolenia w ramach Akademii Pielęgniarstwa Onkologicznego

17.09.2021

Ruszył kolejny cykl bezpłatnych szkoleń szkoleń online dla pielęgniarek/pielęgniarzy i personelu medycznego. Do końca roku zaplanowano 10 spotkań w następujących modułach tematycznych: leczenie przeciwnowotworowe, wybrane problemy współczesnej onkologii, powikłania w leczeniu onkologicznym, leczenie wspomagające w onkologii, praktyczne aspekty opieki pielęgniarskiej.

esmo logo

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

17.09.2021

According to results from a prospective, open-label, phase III study conducted among the postmenopausal patients with stage I to III breast cancer who were treated with 2 to 3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in longer disease-free survival (DFS) and overall survival (OS) compared to the treatment with 2 to 3 years of letrozole.

esmo logo

Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC Regimen in Patients with MIBC

17.09.2021

For the first time since 20 years in the bladder peri-operative setting, the authors have design a randomised phase III controlled study comparing the efficacy of GC or dd-MVAC in patients for whom chemotherapy has been decided before or after surgery.

esmo logo

Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer

17.09.2021

In the first randomised, controlled study to explore the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel compared to nab-paclitaxel alone, combined treatment improved progression-free survival (PFS) and showed a favourable safety profile among the women with recurrent platinum-resistant and/or platinum-refractory ovarian cancer.

esmo logo

Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily Pretreated B-Cell Non-Hodgkin Lymphoma

16.09.2021

Epcoritamab is a highly selective and potent bispecific antibody for CD3 and CD20 that induces T-cell-mediated cytotoxic activity against CD20-positive malignant B-cells. In a first-in-human phase I/II study subcutaneous epcoritamab was safely administered in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

esmo logo

Long-Term, Poorly Controlled Diabetes May Impair Efficacy of Immune Checkpoint Inhibitors

16.09.2021

How diabetes mellitus affects the efficacy of immune checkpoint inhibitors (ICIs) is yet to be defined. It prompted the investigators from 21 Italian and 1 UK institutions to evaluate the impact of diabetes mellitus in a retrospective cohort of patients with advanced cancer treated with a single-agent ICI.

asco logo

Considering Cost and Toxicity Choosing Between CDK4/6 and mTOR Inhibitors for the Treatment of Breast Cancer

16.09.2021

The CDK4/6 pathway and PI3K/AKT/mTOR pathway are implicated in the development of resistance to endocrine therapy. In vivo studies show that PI3K and mTOR inhibition can restore sensitivity to endocrine therapy.

asco logo

Determining How to Treat Chemosensitive Sarcomas: Evaluating Patient Risk of Recurrence and Death Plays an Important Role

15.09.2021

The question of using adjuvant chemotherapy in adult patients with soft tissue sarcoma is an important one. Although most patients who present with localized disease can be cured with wide local excision alone, previous data showed that about half of these patients will die of subsequent metastatic disease.

esmo logo

New Safety Signal for Use of Ibrutinib in Combination with Rituximab and ACE Inhibitors

15.09.2021

An interim analysis of the clinical study suggested that the risk of sudden or cardiac death in patients on an ACE inhibitor when entering the study was increased in patients randomised to ibrutinib and rituximab, compared to those randomised to fludarabine, cyclophosphamide and rituximab.

NICE logo

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

15.09.2021

Abemaciclib plus fulvestrant is recommended as an option for treating hormone receptor‑positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer in adults who have had endocrine therapy only if exemestane plus everolimus is the most appropriate alternative to a cyclin‑dependent kinase 4 and 6 (CDK 4/6) inhibitor.

esmo logo

Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases

14.09.2021

In the TROG 13.01 phase II randomised clinical study that compared single-fraction versus multifraction stereotactic ablative radiation therapy (SABR) in patients with pulmonary metastases, the researchers demonstrated that neither arm was superior in terms of safety, efficacy, or symptom burden; however, single-fraction SABR is of shorter duration and more efficient to deliver.

esmo logo

Lack of Evidence for the Use of Telemedicine in the Prevention and Surveillance for Recurrences and New Cancers

13.09.2021

There is a lack of evidence on the use of telemedicine in the prevention and surveillance for recurrences and new cancers, as well as in the management of chronic medical conditions, and health promotion. The findings were published on 9 September 2021 in the Annals of Oncology.

ESTRO logo

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma

13.09.2021

Adjuvant temozolomide chemotherapy, but not concurrent temozolomide chemotherapy, was associated with a survival benefit in patients with 1p/19q non-co-deleted anaplastic glioma. Clinical benefit was dependent on IDH1 and IDH2 mutational status.

esmo logo

Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the Results of a Customised Next-Generation Sequencing Panel

10.09.2021

Results of a molecular-based approach using a customised next-generation sequencing (NGS) panel at a single academic institution were published in the British Journal of Cancer. The molecular screening aimed to select the best potential therapeutic strategy for patients with advanced cancer to receive the treatment within the early clinical study programme.

asco logo

Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update

10.09.2021

A significant improvement in invasive and distant disease-free survival constituted a strong signal for an update of the 2020 ASCO-ASTRO-SSO guideline recommendation focused specifically on the role of PARP inhibitors in patients with early-stage, HER2-negative breast cancer and germline BRCA mutations.

esmo logo

No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer with Already Confirmed Germline BRCA Mutations

09.09.2021

According to findings from a prespecified exploratory analysis of the OlympiAD study, in patients with HER2-negative metastatic breast cancer and already confirmed germline BRCA mutations, there is no clear benefit of additional tumour testing for the homologous recombination deficiency (HRD) score or detection of gene-specific loss of heterozygosity (LOH) to determine if they are likely to respond to the treatment with PARP inhibitor.

ECO logo

Comprehensive Cancer Centres: The Foundation for Beating Cancer Plan and Cancer Mission Success

08.09.2021

The policy paper „Comprehensive Cancer Care Across the EU: Advancing the Vision” provides essential points of advance on implementing the commitment of the European Commission to develop a new EU Network of Comprehensive Cancer Centres and meet an objective of 90% of eligible cancer patients achieving access to such Centres by 2030.

NICE logo

NICE draft guidance recommends apalutamide for treating prostate cancer

08.09.2021

The draft guidance looks at treating prostate cancer in adults which no longer responds to hormone therapy and who are at high risk of the cancer spreading to other parts of their body, or is still sensitive to hormone therapy but has already spread.

NICE logo

Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer

08.09.2021

Nivolumab plus ipilimumab and 2 cycles of platinum-doublet chemotherapy is not recommended, within its marketing authorisation, for untreated metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.

esmo logo

More Than 25 Additional Years Needed to Slow an Increasing Incidence of Oropharyngeal Cancer by Current HPV Vaccination Rate

08.09.2021

According to the projections of the population-based age-period-cohort study performed by a group of the authors from the Johns Hopkins University in Baltimore, who published their findings on 2 September 2021 in the JAMA Oncology, current human papillomavirus (HPV) vaccination rate will have a limited association with overall incidence of oropharyngeal cancer until 2045 because older individuals who are not vaccinated remain at high risk.

esmo logo

Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade in Advanced NSCLC

07.09.2021

Considering specificities of non-small cell lung cancer (NSCLC) biology and corresponding treatment strategies for advanced disease, a group of experts from Memorial Sloan Kettering Cancer Centre in New York, proposed a practical, clinical definition of acquired resistance to PD-(L)1 blockade for use in clinical reports and prospective clinical studies.

ESTRO logo

Phase III Randomised Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC

06.09.2021

This randomised phase III trial did not find a lower probability of cognitive decline in patients with SCLC receiving HA-PCI compared with conventional PCI. No increase in brain metastases at two years was observed in the HA-PCI arm.

esmo logo

Studying Molecular Subtypes of Peritoneal Metastases in Gastric Cancer

06.09.2021

In a study published in the Nature Cancer, the research team from National Cancer Centre Research Institute in Tokyo, Japan took advantage of cancer cells purified from malignant ascites and established corresponding cell lines as the resources for genomic analyses to overcome the technical limitations associated with analyses of primary tumours.

Wykład inauguracyjny im. prof. Tadeusza Koszarowskiego wygłaszany przez prof. Krzysztofa Zieniewicza

XXVII Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej

03.09.2021

W dniach 2-4 września 2021 odbywa się w Poznaniu XXVII Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej, pierwszy zjazd tego Towarzystwa po pandemii z osobistym udziałem jego członków. Przewodniczącym Zjazdu jest prof. Dawid Murawa, obecny Prezes PTChO. Zjazd odbywa się pod patronatem m.in. Marszałka Senatu prof. Tomasz Grodzkiego, który sam jest chirurgiem zajmującym się leczeniem chorych onkologicznych.

esmo logo

A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms Established Prognostic Models in MDS

02.09.2021

New prediction model can provide probability of survival and leukaemia transformation at diagnosis of myelodysplastic syndrome and throughout a patient's disease course.

asco logo

What Do Oncology Providers Need to Know About Cannabis Use in Patients With Cancer?

02.09.2021

Recent reports (USA) suggest 20% to 40% of all patients with cancer use cannabis in some form during or after treatment. Among those patients who use cannabis, two-thirds report using it to help manage pain, anxiety, or insomnia. However, the science and clinical knowledge of cannabis fall significantly behind state laws.

asco logo

Quality Care in Oncology Shifts to Implementing Change: A Look at Quality Research in Lung Cancer

02.09.2021

Assuring high-quality, equitable care for every patient with cancer is a key part of ASCO's mission. According to Devika Das, MD, MSHQS, a member of ASCO's International Quality Task Force, the field of quality studies is in the beginning stages of a metamorphosis that will likely only accelerate over the next few years.

asco logo

Molecular Testing in Patients With Early Non—Small Cell Lung Cancer

01.08.2021

The discovery of molecular alterations has led to a significant improvement in the outcomes of patients with advanced lung cancer. Recently, the results of the ADAURA study established osimertinib as the standard-of-care adjuvant therapy in resectable NSCLC with sensitizing mutations in the EGFR gene, marking the entry of targeted therapy in the treatment landscape of early-stage disease.

esmo logo

eUpdate – Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations

01.09.2021

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging and systemic and local therapy

esmo logo

Surveillance and Early Cancer Detection are Associated with Improved Survival in Constitutional Mismatch Repair Deficiency Syndrome

01.09.2021

Constitutional mismatch repair deficiency syndrome is a cancer predisposition syndrome associated with inheritance of biallelic pathogenic variants in mismatch repair (MMR) genes leading to deficient MMR during DNA replication. It is characterised by early-onset synchronous and metachronous multiorgan tumours.

esmo logo

Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node Micrometastases the Morbidity of Lymphadenectomy

31.08.2021

Inguinofemoral radiotherapy for patients with vulvar cancer and micrometastases in the sentinel node is safe alternative for inguinofemoral lymphadenectomy according to the GROINSS-V-II study investigators. The radiotherapy side effects were acceptable with less frequent treatment-related morbidity compared with inguinofemoral lymphadenectomy.

NCCN logo

Information on Third mRNA COVID-19 Vaccine Dose Added to NCCN Guidance for People with Cancer

30.08.2021

NCCN announced significant updates to the NCCN: Cancer and COVID-19 Vaccination guidance. This is the fourth version of NCCN’s COVID-19 vaccination guide and incorporates the latest data plus recent approvals from the FDA and CDC regarding a third mRNA vaccine dose for immunocompromised people.

esmo logo

FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma

30.08.2021

FDA approved ivosidenib for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.

ESTRO logo

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer

30.08.2021

Neoadjuvant durvalumab combined with stereotactic body radiotherapy is well tolerated, safe, and associated with a high major pathological response rate. This neoadjuvant strategy should be validated in a larger trial.

esmo logo

Impact of Multigene Germline Genetic Testing on Selection of Germline-Directed Therapy in Patients with Metastatic or Recurrent Cancer

27.08.2021

27.08 Among 11,947 patients with metastatic or recurrent cancer that spanned across more than 50 different tumour types, 8% of patients had a tumour with germline alteration considered therapeutically actionable and 3.2% of these patients received germline genotype–directed treatment.

HIPEC.pl logo

Kurs „Perioperative Management in CRS and HIPEC of Peritoneal Malignancy”

27.08.2021

W dniach od 10 do 15 grudnia odbędą się 9. warsztaty interdyscyplinarne „Perioperative Management in CRS and HIPEC of Peritoneal Malignancy”. Organizatorem warsztatów jest Charité - University Medicine Berlin. Warsztaty odbywają się pod patronatem towarzystw medycznych: DGAV, BDC, BDA, DGAI oraz ESSO.

esmo logo

Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from Conventional Histopathological Slides

26.08.2021

Findings from one of the first studies to investigate the use of artificial intelligence in the pathological management of soft tissue sarcoma (STS) show that a deep learning model was able to classify five of the most common STS subtypes from histology alone. When aided by the deep learning model, pathologists were more accurate, faster, and more certain in their diagnosis.

NCCN logo

JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions

26.08.2021

Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, according to a new study published in the August 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network.

asco logo

Novel Trial Finds Benefit of Combination Chemotherapy for Patients With Relapsed/Progressive Rhabdomyosarcoma

26.08.2021

Findings from the first randomized controlled trial of temozolomide plus vincristine-irinotecan (VI) among pediatric and adult patients with relapsed/progressive rhabdomyosarcoma (RMS; VIT-0910 trial) suggest the combination chemotherapy improves efficacy over VI alone.

asco logo

Case Study: Initial Immunotherapy or Chemotherapy in Advanced, Cisplatin-Ineligible Bladder Cancer

25.08.2021

The role of immunotherapy as first-line treatment for advanced urothelial cancer in patients not eligible for cisplatin therapy is uncertain. Carboplatin-containing regimens were previously the standard of care, but outcomes were poor.2 Accelerated approvals were given to atezolizumab and pembrolizumab based on phase II data.

asco logo

The Future of Immunotherapy in Endometrial and Ovarian Cancers

25.08.2021

The phase III KEYNOTE-775 study compared combination lenvatinib/pembrolizumab with standard single-agent chemotherapy in 827 patients with advanced, metastatic, or recurrent EC progressing after prior platinum-based chemotherapy. Immunotherapy led to a significant improvement of ORR, PFS, and OS when compared to chemotherapy.

PTChO logo

Kurs Diagnostyka inwazyjna gruczołu piersiowego

25.08.2021

Polskie Towarzystwo Chirurgii Onkologicznej zaprasza na kurs „Diagnostyka inwazyjna gruczołu piersiowego”, który odbędzie się 1 września 2021 w Szpitalu Uniwersyteckim w Zielonej Górze. Ilość miejsc ograniczona do 10 osób – decyduje kolejność zgłoszeń.

NICE logo

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

25.08.2021

Pemigatinib is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after systemic therapy in adults.

esmo logo

Molecular Determinantion of Outcomes in a Study with Pembrolizumab for Advanced Gastric/GEJ Cancer

25.08.2021

In KEYNOTE-061 randomised study, PD-1 blockade with immune checkpoint inhibitor (ICI) pembrolizumab did not significantly improve overall survival (OS) over paclitaxel in second-line treatment for advanced gastric/gastro-oesophageal junction (GEJ) adenocarcinoma with PD-L1 combined positive score (CPS) ≥1.

esmo logo

FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma

24.08.2021

FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection. Evidence for efficacy in the adjuvant treatment of patients with high-risk urothelial carcinoma is based on the results of CHECKMATE-274 study.

Cancer Journal - baner

Statyny poprawiają przeżywalność pacjentek z potrójnie negatywnym rakiem piersi

24.08.2021

Badanie prowadzone przez naukowców z University of Texas MD Anderson Cancer Center wykazało znaczący związek między przyjmowaniem leków obniżających poziom cholesterolu, powszechnie znanych jako statyny, a wskaźnikami przeżycia pacjentek z potrójnie negatywnym rakiem piersi (TNBC).

esmo logo

TILs Therapy Shows Promise in the Management of Anti-PD-1-Resistant Metastatic NSCLC

23.08.2021

A cell therapy with autologous tumour-infiltrating lymphocytes (TILs), followed by maintenance nivolumab, was safe and clinically active upon initial progression on nivolumab monotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

ESTRO logo

The HILUS-Trial-a Prospective Nordic Multicenter Phase II Study of Ultracentral Lung Tumours Treated With Stereotactic Body Radiotherapy

23.08.2021

On the basis of the presented data, 7.0 Gy × 8.0, prescribed to the planning target volume-encompassing isodose, should not be used for tumours located within 1 cm from the main bronchi and trachea. Group B-type tumours may be considered for the treatment on the basis of an individual risk-benefit assessment.

esmo logo

FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumours

20.08.2021

FDA granted accelerated approval to dostarlimab-gxly for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.

asco logo

Guideline Rapid Update Provides New Direction on the Care of Patients With Residual Disease in Locally Advanced Esophageal Cancer

20.08.2021

An ASCO guideline rapid update is revising recommendations for the management of locally advanced esophageal carcinoma to include provision of nivolumab following adjuvant chemoradiotherapy (CRT) and surgery.

AACR logo

Adoptive Transfer of Tumor-infiltrating Lymphocytes May Be Less Effective in Patients With Pretreated Metastatic Melanoma

18.08.2021

Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes as patients naive to these treatments, according to results of a study published in Clinical Cancer Research Journal.

esmo logo

Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients with SCLC

19.08.2021

The results from a phase III clinical study provide the first clinical evidence that sparing the hippocampus during prophylactic cranial irradiation (PCI) better preserves cognitive function in patients with small-cell lung cancer (SCLC).

asco logo

Clinical Challenges in the Management of Clinical Stage I Seminoma

19.08.2021

Seminoma is a relatively rare and highly curable disease that occurs mainly in young men. Treatment usually affects the patient's quality of life with long-term toxicities. The treatment of clinical stage I seminoma is still debatable. Clinical management is variable and guidelines do not recommend one therapy over another.

PTChO logo

Kurs „Wprowadzenie do specjalizacji z chirurgii onkologicznej”

18.08.2021

Przed XXVII Zjazdem PTChO, odbędzie się dwudniowy kurs „Wprowadzenie do specjalizacji z chirurgii onkologicznej”. Kurs odbędzie się w dniach 1 i 2 września w Poznaniu, w Hotelu Novotel Poznań Centrum.

NICE logo

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer

18.08.2021

Abiraterone with prednisone or prednisolone plus androgen deprivation therapy (ADT) is not recommended, within its marketing authorisation, for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer in adults.

esmo logo

Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced NSCLC

18.08.2021

Study findings point to potential to integrate prior antibiotic exposure in decision-making process for first-line treatment of advanced non-small cell lung cancer.

asco logo

Patients Want Complementary and Alternative Treatments; Here's How to Implement Integrative Oncology Into Practice

18.08.2021

Treatment of cancer, as it turns out, requires much more than establishing and executing a drug therapy plan. To address some of these questions, an oncologist might refer the patient to a nutritionist and to a physical therapist.

Nature Medicine – okładka wydania sierpień 2021

Obiecujące wyniki badań klinicznych nowej terapii niedrobnokomórkowego raka płuca

17.08.2021

Immunoterapia stała się ważnym narzędziem w leczeniu raka płuc, zwłaszcza terapie z wykorzystaniem inhibitorów punktów kontrolnych, które blokują wybrane mechanizmy kontrolne systemu immunologicznego, pozwalając komórkom odpornościowym na efektywniejsze rozpoznawanie i zabijanie komórek nowotworowych.

esmo logo

Clinical Practice Guidelines – Care at the End of Life

17.08.2021

This ESMO Clinical Practice Guideline provides key recommendations for managing the last weeks and days of life for the adult cancer patient with advanced cancer.

esmo logo

FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease

17.08.2021

FDA approved belzutifan a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery.

ESTRO logo

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

16.08.2021

Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations are needed.

esmo logo

A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical Utility in NETs Management

16.08.2021

The 51-gene expression-based liquid biopsy accurately diagnoses neuroendocrine tumours and is an effective surrogate marker compared to chromogranin A.

NICE logo

NICE draft guidance recommends abemaciclib for advanced breast cancer

12.08.2021

Abemaciclib plus fulvestrant is recommended as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had endocrine therapy.

esmo logo

Elucidating a Risk of Developing Second Primary Malignancy During and After Treatment with PARP Inhibitors

12.08.2021

Although PARP inhibitors interfere with DNA repair processes leading to warnings in terms of risk for developing second primary malignancies, findings from a systematic review and safety meta-analysis of placebo-controlled randomised controlled studies are reassuring for patients starting PARP inhibitors in the first-line setting that there is no increased risk of developing second primary malignancies.

esmo logo

FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma

12.08.2021

FDA approved the combination of lenvatinib plus pembrolizumab for first-line treatment of adult patients with advanced renal cell carcinoma. Evidence for efficacy of combination treatment is based the results of the CLEAR study.

asco logo

Primary and Secondary Endpoints for Sarcoma Clinical Trials

12.08.2021

Through the years, doxorubicin has been considered the gold standard as first-line cytotoxic chemotherapy in most patients with advanced soft-tissue sarcomas. This was based on the landmark EORTC 62012 study.

asco logo

Pathogenic Variant Probability in High-Risk Genes Supports Genetic Testing in Older Women With Breast Cancer

12.08.2021

here is mounting evidence that all women diagnosed with breast cancer, including those age 65 and older at diagnosis, should receive genetic testing. This is supported by results from a recent study.

asco logo

Fertility Preservation Before Cancer Treatment: Aspirations Versus Attainment

11.08.2021

A major gap remains between guidelines advocating for information and counseling on fertility preservation for all patients at risk of cancer-related infertility and the reality of practice in oncology settings.

esmo logo

Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole in Breast Cancer

11.08.2021

Final results of the Study of Letrozole Extension (SOLE) indicate that treatment with intermittent letrozole did not show superiority in terms of disease-free survival compared with continuous treatment in the extended adjuvant setting for postmenopausal women with hormone receptor-positive breast cancers.

Akademia hematologii 2021 - baner wydarzenia

Akademia hematologii 2021

10.08.2021

PZWL razem z kierownikiem naukowym prof. dr hab. n. med. Jadwigą Dwilewicz-Trojaczek, zaprosił wybitnych specjalistów hematologów i onkologów do przedstawienia aktualnej wiedzy na temat diagnostyki oraz leczenia nowotworów układu krwiotwórczego i chłonnego.

esmo logo

COVID-19 Vaccination Efficient in Patients with Cancer Who Receive Active Anticancer Treatment

09.08.2021

Prof. Jean-Yves Blay of the Université Claude Bérard in Lyon, France and colleagues reported on 2 August 2021 in the Annals of Oncology findings from an analysis of the clinical efficacy of COVID-19 vaccination in a series of 1503 patients with cancer under active treatment for cancer.

ESTRO logo

Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases

09.08.2021

Stereotactic body radiotherapy at a dose of 24 Gy in two daily fractions was superior to conventional external beam radiotherapy at a dose of 20 Gy in five daily fractions in improving the complete response rate for pain. These results suggest that use of conformal, image-guided, stereotactically dose-escalated radiotherapy is appropriate in the palliative setting for symptom control for selected patients with painful spinal metastases.

AACR logo

First-in-class Histone Deacetylase Inhibitor Gel Shows Promise for the Treatment of Patients with Basal Cell Carcinoma

06.08.2021

Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation, showed signs of clinical efficacy in patients with basal cell carcinoma, according to results from a phase II clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

esmo logo

ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to Neoadjuvant Chemotherapy to TNBC

06.08.2021

In a monoinstitutional study, the investigators evaluated clinical outcomes in patients with oestrogen receptor (ER)-low positive, HER2-negative, stage I-III breast cancer as compared to patients with triple-negative breast cancer (TNBC) undergoing (neo)adjuvant chemotherapy.

asco logo

The Rise of Chimeric Antigen Receptor T-Cell Therapy and the Path Forward

05.08.2021

A new era in cancer treatment dawned with the first FDA approval for CD19 antigen–directed chimeric antigen receptor (CAR) T-cell therapy in 2017 for acute lymphoblastic leukemia. Since then, new constructs have been approved for high-grade B-cell lymphomas, mantle cell lymphoma, follicular lymphoma, and multiple myeloma.

Akademia leczenia wspomagającego w onkologii 2021 - baner wydarzenia

Akademia leczenia wspomagającego w onkologii 2021

05.08.2021

PZWL zaprasza na kolejną edycję wirtualnej akademii. Wybitni specjaliści omówią najbardziej palące tematy leczenia wspomagającego w onkologii. Wydarzenie jest bezpłatne i przeznaczone dla lekarzy wszystkich specjalizacji uczestniczących w procesie leczenia chorych na nowotwory.

esmo logo

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

05.08.2021

Findings from phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival (PFS) in third-line or later treatment of patients with molecularly unselected unresectable or metastatic gastrointestinal stromal tumour.

esmo logo

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

04.08.2021

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on standard-of-care platinum-based chemotherapy.

asco logo

Examining Recent Advances in the Management of Brain Metastases in HER2-Positive Breast Cancer

04.08.2021

Recently, interest has risen regarding HER2-directed therapies in central nervous system (CNS) metastases for patients with HER2-positive metastatic breast cancer; new data have shown promising activity among newer HER2-targeted agents.

asco logo

Ixazomib Shows Clinically Meaningful, But Not Statistically Significant, Survival Benefit in Patients With Relapsed/Refractory Multiple Myeloma

04.08.2021

Final overall survival (OS) analysis of the phase III TOURMALINE-MM1 trial found that ixazomib produces clinically meaningful, albeit statistically insignificant, improvement in OS in patients with relapsed/refractory multiple myeloma.

ESTRO logo

Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status

03.08.2021

Despite adjustment for previously unmeasured confounders, breast-conserving surgery with radiotherapy yielded better survival than mastectomy irrespective of radiotherapy. If both interventions are valid options, mastectomy should not be regarded as equal to breast conservation.

esmo logo

First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously Treated CLL

03.08.2021

Phase III study results point to noninferiority of acalabrutinib, while it provides improved safety in patients with previously treated chronic lymphocytic leukaemia.

esmo logo

FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer

02.08.2021

FDA approved pembrolizumab for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. KEYNOTE-522 study was the basis for approval in the neoadjuvant and adjuvant setting.

Nature Cancer 07/2021 okładka

Rak wątroby – nowa terapia pozwala na leczenie chirurgiczne pacjentów, którzy według obecnych kryteriów zostali uznani za nieuleczalnie chorych

02.08.2021

Połączenie kabozantynibu, leku będącego inhibitorem kinazy, oraz stosowanego w immunoterapii niwolumabu, może umożliwić leczenie chirurgiczne u niektórych pacjentów z rakiem wątroby, którzy ze względu na stopień zaawansowania nowotworu normalnie zostaliby uznani za przypadki nieoperacyjne.

EORTC logo

Combined hormone/radiotherapy treatment improves event-free and disease-free survival in patients with localised intermediate risk prostate cancer

30.07.2021

Adding ADT to EBRT to patients with localised intermediate risk prostate cancer significantly increases their event-free survival (EFS)1 and disease-free survival (DFS)2, and these effects are still evident after 12 years of median follow-up, say the investigators in the latest results from an EORTC trial published in The Journal of Clinical Oncology this week.

asco logo

Guideline Update Addresses Treatments for HER2-Negative Advanced Breast Cancer

30.07.2021

In light of findings from multiple recent clinical trials in HER2-negative metastatic breast cancer, ASCO has revised its treatment recommendations to inform more evidence-based care for metastatic breast cancer. This guideline update provides important clinical guidance about the new use of immune checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.

asco logo

New Evidence Drives Need for Revised Guideline on Hormone-Sensitive Advanced Breast Cancer

30.07.2021

A recently updated ASCO guideline offers both new and revised guidance on the treatment of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer. Update encourages use of CDK4/6 inhibitors, alpelisib.

esmo logo

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

29.07.2021

EMA adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Imatinib Koanaa, intended for the treatment of leukaemia and gastrointestinal stromal tumours.

asco logo

Novel Therapies for TNBC Drive Advancements in Breast Cancer

29.07.2021

During the last year, a flurry of clinical trial data have provided greater insight into mechanisms of novel therapies for breast cancer management. Some of these data, including abstracts presented during the 2021 ASCO Annual Meeting, have wide practice-changing implications in triple-negative breast cancer (TNBC) or patients with high-risk, HER2-negative, early-stage disease.

asco logo

Advances in Targeted Therapies, Immunotherapy Improve Treatment Options for Patients With Lung Cancer

29.07.2021

Major advances in lung cancer announced during the 2021 ASCO Annual Meeting follow a year of stunning progress in targeted therapies and immunotherapy that has energized the field. We have seen more progress in the development of targeted therapies and improvement in the lives of our patients in the last 5 years than over the past 25 years in the lung cancer space.

asco logo

Beyond BRCA1/2: Two Large Studies Shed Light on Moderate Breast Cancer Genes

28.07.2021

Recent analysis of large case-control data sets allows for the assessment of many additional genes associated with breast cancer, including ATM, BARD1, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, and RAD51D, and offers compelling insights on hereditary breast cancer genetics.

NICE logo

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

28.07.2021

Clinical trial evidence suggests that nivolumab plus ipilimumab may extend how long people live. The most relevant trial did not directly compare nivolumab plus ipilimumab with usual treatments, but indirect comparisons suggest that it substantially increases how long it takes for the cancer to get worse and how long people live.

American Association for Cancer Research logo

Healthy Lifestyle May Help Mitigate High Genetic Risk of Cancer

28.07.2021

Healthy lifestyle factors such as abstinence from smoking and drinking, low body mass index, and exercise correlated with decreased cancer incidence, even in individuals with a high genetic risk, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

esmo logo

Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption

28.07.2021

Updated worldwide estimates of cancers associated with alcohol consumption stratified by gender, tumour localisation and country indicate causal relation of alcohol with a substantial number of cancer cases that could potentially be avoided. Among all new cancers in 2020, 4.1% were related to alcohol consumption.

PTChO logo

Konferencja „Rak piersi – aktualne zalecenia w zakresie leczenia miejscowego i programów lekowych”

27.07.2021

W dniu 3.09.2021 rozpocznie się dwudniowa konferencja „Rak piersi – aktualne zalecenia w zakresie leczenia miejscowego i programów lekowych”. Sesja pierwsza będzie poświęcona problemom radioterapii po rekonstrukcji piersi. Organizatorzy zachęcają polskie ośrodki chirurgiczne i radioterapeutyczne do podzielenia się swoimi doświadczeniami w tym zakresie.

ESTRO logo

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer

26.07.2021

The higher radiotherapy dose of 60 Gy resulted in a substantial survival improvement compared with 45 Gy, without increased toxicity, suggesting that twice-daily thoracic radiotherapy of 60 Gy is an alternative to existing schedules.

American Society for Radiation Oncology logo

ASTRO issues clinical guideline on radiation therapy for soft tissue sarcoma in adults

27.07.2021

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with soft tissue sarcoma (STS).

esmo logo

Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition Genes Continue to Be at Increased Risk of Breast Cancer

27.07.2021

Women over age 65 years with pathogenic variants in cancer predisposition genes rarely benefit from hereditary cancer genetic testing. A population-based study examined whether women in this age category may qualify for clinical genetic testing and magnetic resonance imaging (MRI) screening.

esmo logo

Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab

26.07.2021

Withdrawal concerns the application to extend the use of atezolizumab to include the treatment of early or locally advanced triple-negative breast cancer.

esmo logo

FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma

23.07.2021

FDA approved pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

NICE logo

Patients with rare bile duct cancer set to benefit from life extending treatment

22.07.2021

Some people who have a rare form of bile duct cancer are set to benefit from life-extending treatment pemigatinib after NICE published final draft guidance today (22nd July 2021).

esmo logo

Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant Neurocognitive Decline

22.07.2021

Over a 5-year follow-up interval, frail young adult survivors of childhood cancers experienced significantly larger declines than nonfrail survivors in memory, attention, processing speed, and executive function domains.

esmo logo

Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced Cutaneous Squamous Cell Carcinoma

21.07.2021

The results of the second interim analysis of the KEYNOTE-629 study that include initial data for the locally advanced cohort and updated data for the recurrent/metastatic cohort of patients with cutaneous squamous cell carcinoma confirm durable pembrolizumab antitumour activity and promising survival in both settings.

asco logo

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer

21.07.2021

Based on data from the CROWN study, lorlatinib is now approved by the U.S. Food and Drug Administration for use in patients with newly diagnosed advanced ALK-positive non–small cell lung cancer (NSCLC), joining ceritinib, alectinib, brigatinib, and ensartinib.

esmo logo

Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab

20.07.2021

In a single-arm, open-label phase II study, the investigators evaluated pembrolizumab in patients with recurrent mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) endometrial cancer.

ESTRO logo

MRI-guided adaptive brachytherapy in locally advanced cervical cancer

19.07.2021

Chemoradiotherapy and MRI-based IGABT result in effective and stable long-term local control across all stages of locally advanced cervical cancer, with a limited severe morbidity per organ. These results represent a positive breakthrough in the treatment of locally advanced cervical cancer, which might be used as a benchmark for clinical practice and all future studies.

esmo logo

FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease

19.07.2021

FDA approved belumosudil, a kinase inhibitor, for adult and paediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

esmo logo

Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies

16.07.2021

Team of scientists investigated clinical factors associated with higher risk for severe COVID-19 in patients with haematological malignancies. They wrote in the Annals of Oncology that the coronavirus infection itself, rather than cytokine storm, lead to severe and lethal COVID-19 in these patients.

AACR logo

Ficlatuzumab Plus Chemotherapy Shows Promise for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

16.07.2021

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia, according to results published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

ECO logo

New Report - Primary Prevention: United for Action

15.07.2021

40% of cancers are preventable. For this reason, both the European Union and World Health Organization actively support countries in policy propositions that can assist in addressing modifiable cancer risks. But are there opportunities to move faster and go further? A new report by the European Cancer Organisation suggests so.

esmo logo

Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and Positive Results on MRI Non-inferior to Standard Biopsy

15.07.2021

In a study of population-based screening by invitation, the results showed that among men with elevated PSA levels, combined biopsy performed only in men who had positive results on magnetic resonance imaging (MRI) was non-inferior to standard biopsy for detecting clinically significant prostate cancer.

asco logo

Comprehensive Cancer Rehabilitation: A Valuable Component of Effective Survivorship Care

15.07.2021

The National Cancer Institute definition of survivorship stipulates that a cancer survivor as an individual is considered to be a survivor from the time of diagnosis to the end of life. It acknowledges that cancer treatment and its consequences do not end when a specific cancer-directed therapy ends, while also implying that the road to recovery and adaptation can begin as soon as a patient is diagnosed.

asco logo

Adjuvant Immunotherapy Guided by ctDNA in Patients With High-Risk Muscle-Invasive Bladder Cancer

15.07.2021

Approximately 50% of patients with muscle-invasive urothelial carcinoma develop metastatic disease within 2 years of radical cystectomy alone, which commonly leads to death.1 Clinicians and researchers have strived for decades to improve this metastasis rate by integrating systemic therapy.

asco logo

Incremental Progress, Reassuring Results Featured Among Gynecologic Malignancies Research at 2021 ASCO Annual Meeting

14.07.2021

Although several studies in gynecologic malignancies have potential to change practice down the road, the OUTBACK trial on adjuvant chemotherapy in cervical cancer was the most impactful work presented at this year's Annual Meeting.

asco logo

Risks and Benefits of Immunotherapy Versus Chemotherapy in Patients With Advanced Prostate Cancer

14.07.2021

Cabazitaxel has proven benefit as a second-line therapy for patients with mCRPC who have progressed rapidly (< 12 months) through prior ASTI treatment. Immunotherapy for prostate cancer remains under clinical investigation, with pembrolizumab indicated only for prostate cancers with MSI-high or TMB-high molecular phenotypes.

.
asco logo

Adjuvant Platinum Chemotherapy Does Not Improve Outcomes in Patients With Triple-Negative Breast Cancer With Residual Disease

14.07.2021

Recently published findings from the phase III EA1131 trial show that, compared to capecitabine, adjuvant platinum chemotherapy does not improve outcomes in patients with triple-negative breast cancer (TNBC) with residual disease.

esmo logo

FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple Myeloma

14.07.2021

FDA approved daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.

esmo logo

FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma

13.07.2021

FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.

ESTRO logo

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck

12.07.2021

The primary objective of prolonging progression-free survival with avelumab plus chemoradiotherapy followed by avelumab maintenance in patients with locally advanced squamous cell carcinoma of the head and neck was not met. These findings may help inform the design of future trials investigating the combination of immune checkpoint inhibitors plus CRT.

esmo logo

FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer

12.07.2021

FDA approved enfortumab vedotin-ejfv, a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD1 or PD-L1 inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

esmo logo

Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab Therapy for Advanced Gastric Cancer

09.07.2021

A team of investigators from Japan detected several genomic pathways and bacterial genera in the pre-treatment gut microbiome of patients with advanced gastric cancer that were significantly associated with survival times following treatment with nivolumab. These findings were presented at the ESMO World Congress on Gastrointestinal Cancer 2021.

asco logo

Longer-Term Follow-Up of Breast Cancer Trials Add Further Insight Into Efficacy of Promising Combination Regimens

08.07.2021

Several pivotal trials in recent years have contributed to greater understanding of the durability and efficacy of certain novel combination regimens for breast cancer. Long-term follow-up data from three trials HER2CLIMB, PALOMA-3, and MONALEESA-3—further established these therapeutic regimens as potentially important components of clinical care.

asco logo

The Future of Geriatric Oncology: Moving From Assessment to Implementation

08.07.2021

Research has repeatedly shown that geriatric assessment, toxicity risk tools, comanagement strategies, and multidisciplinary care models are more accurate than traditional performance status metrics to evaluate older patients with cancer.

esmo logo

Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally Advanced Rectal Cancer

08.07.2021

Many patients with locally advanced rectal cancer receiving a preoperative regimen of standard chemoradiotherapy plus avelumab achieved pathological complete response and the majority of patients showed a major pathological response, according to findings from a phase II AVANA study presented at the ESMO World Congress on Gastrointestinal Cancer 2021.

esmo logo

EMA Recommends Granting a Conditional Marketing Authorisation for Tafasitamab

08.07.2021

It is intended for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT).

NICE logo

Enzalutamide for treating hormone-sensitive metastatic prostate cancer

07.07.2021

Enzalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults.

NICE logo

Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy

07.07.2021

Nivolumab is recommended as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if: their tumours are PD-L1 positive, and it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and they have not had a PD-1 or PD-L1 inhibitor before.

esmo logo

Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and Radiographic Progression in Metastatic Prostate Cancer

07.07.2021

07.07 Novel liquid biopsy technology to collect mRNA from circulating tumour cells (CTCs) may be used to measure expression of androgen receptor (AR) splice variants, AR targets, and neuroendocrine prostate cancer markers.

asco logo

Managing Acquired Resistance in EGFR-Mutated Non–Small Cell Lung Cancer

07.07.2021

The management of acquired resistance to EGFR-mutated non–small cell lung cancer (NSCLC) has undergone significant change since osimertinib was approved by FDA for first-line treatment of the most common EGFR-activating mutations, EGFR E19del and L858R, in December 2020.

asco logo

Understanding the Role of Lifestyle in Cancer Development

07.07.2021

At least 42% of newly diagnosed cancers in the United States are potentially avoidable because they are attributable to lifestyle factors such as smoking, alcohol consumption, poor nutrition, and lack of physical activity.

asco logo

Gastrointestinal Cancers Present Unique Challenges to Older Adults

07.07.2021

Age is perhaps the most significant risk factor for cancer incidence. With increased longevity of the population, early detection, and more effective therapies, the number of older patients with cancer and survivors of cancer will continue to rise.

Baner konferencji „UroScrabble”

Konferencja „UroScrabble” 2021

07.07.2021

20 listopada 2021 roku, w sobotę, odbędzie się konferencja „UroScrabble”. Wydarzenie kierowane jest do urologów, onkologów, nefrologów, lekarzy rodzinnych oraz wszystkich specjalistów zainteresowanych tematyką wyszczególnioną w programie.

esmo logo

Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer

06.07.2021

Trastuzumab deruxtecan demonstrated clinically meaningful benefit across specific subgroups of patients with HER2-positive and HER2-low advanced gastric cancer according to findings from a post-hoc exploratory biomarker analysis presented at the ESMO World Congress on Gastrointestinal Cancer 2021.

ESTRO logo

Increasing the value of radiotherapy in breast cancer

05.07.2021

Radiotherapy plays an important role in breast cancer management. After breast-conserving surgery, radiotherapy reduces the probability of recurrence and improves overall survival. Adjuvant whole-breast irradiation (WBI) was previously delivered in daily treatments, given over five–six weeks. These treatments, coupled with other multidisciplinary advances such as increasing the use of systemic therapy, yielded outstanding outcomes.

esmo logo

First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable Safety in BRAF V600E–Mutated mCRC

05.07.2021

Almost half of patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer (mCRC), who generally have a poorer prognosis, demonstrated response and 88% showed disease control following combination treatment with encorafenib, binimetinib, and cetuximab.

esmo logo

Preoperative ctDNA Levels Are Detectable in the Majority of Patients with Resectable Colorectal Cancer

05.07.2021

A team of investigators in Japan used a personalised assay for circulating tumour DNA (ctDNA) levels in plasma to monitor minimal residual disease following surgery in patients with resectable colorectal cancer. Their subgroup analysis found statistically significant associations between ctDNA levels and the pathological disease stage.

esmo logo

ctDNA Analysis is Feasible for Detection of Minimal Residual Disease After Treatment Across a Variety of MMRd Tumour Types

02.07.2021

Circulating tumour DNA analysis is a feasible tumour agnostic approach for evaluation of the efficacy of checkpoint blockade in patients at high risk of recurrence.

esmo logo

Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic Colorectal Cancer

02.07.2021

Three studies delineating the prevalence of KRAS mutations in gastrointestinal and colorectal cancer, with specific focus on the KRAS G12C mutation, and an evaluation of patient outcomes according to the mutation status were presented at the ESMO World Congress on Gastrointestinal Cancer 2021.

asco logo

Early Data Raises Hope for Several Types of Difficult-to-Treat Brain Tumors

02.07.2021

Over the past decade, immunotherapies have transformed the treatment of patients with certain aggressive cancers, including lung and melanoma. However, less progress has been made in difficult-to-treat brain tumors. But data presented during the 2021 ASCO Annual Meeting offered promising findings for patients with unique subtypes of brain tumors.

asco logo

New Research Exploring the Role of Pembrolizumab in Locally Advanced Oral Cancers Warrants Further Investigation

02.07.2021

The incidence of oral cancer is increasing in young adults and in adults who have never smoked, representing a high unmet need. New research on neoadjuvant pembrolizumab suggests that immunotherapy may play a promising role in locally advanced oral cancers.

esmo logo

Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower Chemotherapy Doses

02.07.2021

Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021.

esmo logo

Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use

02.07.2021

Doctors and patients are being advised to reduce unnecessary antibiotic use following new data suggesting that these medicines may increase the risk of cancer of the large intestine (colon), especially in people under 50 years.

esmo logo

The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular Carcinoma

01.07.2021

A novel anti-PD1 agent, tislelizumab, is under development for the treatment of patients with solid tumours and has demonstrated clinical benefit in unresectable hepatocellular carcinoma (HCC), according to findings from a phase II study presented at the ESMO World Congress on Gastrointestinal Cancer 2021.

esmo logo

EMA Recommends Extension of Therapeutic Indications for Nivolumab

01.07.2021

New indication concerns adjuvant treatment of oesophageal or gastro-oesophageal junction cancer with residual disease following prior neoadjuvant chemoradiotherapy.

asco logo

How Community Oncologists Can Address the Sexual Health of Female Patients With Cancer

01.07.2021

Sexual health problems, including genital symptoms, changes in sexual response, and psychosocial issues, are prevalent in women with cancer, yet these patients are rarely asked about their sexual concerns. Oncology teams must commit to assessing and addressing sexual health, and multiple resources are available for the busy professional.

asco logo

2021 Plenary Session Showcased Advances in Adjuvant Therapy, Treatment of Metastatic Cancers

01.07.2021

The ASCO Annual Meeting Plenary Session consistently features some of the most important treatment advances that have occurred over the past year across the broad spectrum of cancers. We asked experts to share their thoughts on the five randomized phase III clinical trials presented during the 2021 Session and how the results of these trials are likely to influence clinical practice.

asco logo

ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer

01.07.2021

Ovarian cancer carries a heavy morbidity and mortality burden, particularly in settings and regions of the globe that feature significant limitations in health care resources. Given that ovarian cancer is more lethal than breast cancer, clinicians in resource-limited areas require guidance on the appropriate assessment and treatment of patients with this disease.